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Apoptosis is a genetically regulated form of cell death that occurs when the cell is 
exposed to physiological, pathogenic, or cytotoxic stimuli. Unregulated apoptosis (too 
much or too little apoptosis) at any time from embryogenesis to adulthood, can result in a 
variety of disease states, such as neurodegenerative disorders, autoimmunity, 
cardiovascular disease, liver and kidney problems, and cancer. A reasonable estimation is 
that either too little or too much cell death contributes to half of the main medical 
illnesses for which adequate therapy or prevention is lacking. The apoptotic pathways can 
be initiated by reactive oxygen species (ROS) and inflammatory molecules, both of 
which are believed to be up-regulated in a state of obesity. In addition, multiple studies 
have shown that the risk of developing cardiovascular disease, type 2 diabetes mellitus, 
nonalcoholic fatty liver disease, and certain types of cancers increase with increasing 
degree of obesity in both men and women.  Despite the well characterized association of 
obesity and disease incidence, the mechanisms by which obesity contributes to disease 
pathology are poorly understood. Previously, in our research group, it was shown that 
obese Zucker rats, which are the animal model of human obesity, are more prone to colon 
cancer and hepatic steatosis compare to their relative lean counterparts. Therefore, 
applying Real-Time RT-PCR, the expression levels of some pro- and anti-apoptotic 
members of the BCL-2 family of genes were investigated to figure out the possible effect 
of obesity on apoptotic gene expression levels. Also, apoptotic gene expression patterns 
of obese and lean Zucker rats after DNA damage induction were compared to each other 
in order to find the possible connection of apoptotic gene expression with disease 
progression in obese individuals. This is the first study comparing the expression level of 
BCL-2 family of genes in obese versus lean liver and colon tissue. In this study, it was 
shown that an obese genotype affects pro- and anti-apoptotic gene expression levels and 
patterns whether or not DNA damage has been induced in both liver and colon. The 
results show a clear alteration in apoptotic gene expression levels in obese individuals 
compared to their lean counterparts leading to the proposal that apoptosis may be 
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Chapter 1 Introduction 
1.1 Apoptosis 
 
Apoptosis — the regulated death of a cell — is a complicated process. The decision to 
die cannot be taken easily, and the activities of many genes influence a cell's fate by 
playing a role in its self-destruction programme. Once the decision is made by thd 
organism, proper execution of the apoptotic programme is essential for the coordinated 
activation and execution of multiple sub-programmes. Multi-cellular organisms often 
need to get rid of excess cells, regarding this purpose; they use an organized molecular 
program. As important as cell division and cell migration, regulated cell death allows the 
organism to tightly control cell numbers and tissue size, and to establish homeostasis. 
Programmed cell death acquired a number of names over the past two centuries (1). The 
term apoptosis finally adopted by Currie and co-workers in 1972 to describe a common 
type of programmed cell death that they repeatedly observed in various tissues and cell 
types (2). They noticed that these dying cells shared many morphological features, which 
were distinct from the features observed in cells undergoing pathological and necrotic 
cell death, and they suggested that these shared morphological features should be the 
result of a common and conserved cell death programme (3). Apoptosis can now be 
defined not only by morphology, but also by molecular and biochemical mechanisms. 
Studies within the past few years have revealed that a complex group of molecules that 
make up the “the death machinery” regulates apoptosis. This pathway can be explained as 
an active process of cellular self-destruction with distinctive morphological and 
biochemical features (4). Two major apoptotic pathways have been defined in 
mammalian cells: the death-receptor-mediated or the extrinsic apoptotic pathway and the 
mitochondrial or the intrinsic apoptotic pathway. The extrinsic pathway can be activated 
through cell surface receptors by external stimuli such as growth factor withdrawal, UV 
or γ radiation, chemotherapy agents, free oxygen radicals, and heat shock leading to 
activation of cysteine-aspartic-acid-proteases (Caspases) (5).  The intrinsic pathway is 
activated through mitochondrion as a result of cellular stress and DNA damage (Fig.1). In 
this pathway, the BCL-2 family of genes and proteins are perhaps the most important 
regulators. These proteins can also be responsible for bridging signals from the death-




Figure 1 Death signals  
Modified from (6) 
 
 
BCL-2 family consists of both anti-apoptosis and pro-apoptosis members. While the 
pro-apoptosis members function as sensors for death signals and executors of the death 
program, the anti-apoptosis members inhibit the initiation of the death program.  Also 
caspase cascade activity is essential in both pathways, thus a short description of caspase 
proteins as well as two apoptosis pathways will be provided. The BCL-2 family will be 









1.2 The role of caspases in apoptosis 
Horvitz’s group for the first time discovered the role of caspases in regulation of 
programmed cell death during development of the nematode worm Caenorhabditis 
elegans (7), and because of his efforts in this field, he was awarded the 2002 Nobel Prize 
for studies of the genetic regulation of C. elegans development (8) .  Most of the 
morphological changes that are observed during apoptosis are caused by a set of cysteine 
proteases activated specifically in apoptotic cells. These death proteases are very similar 
to each other in their sequence, and are part of a large protein family known as the 
caspases. Caspases are highly conserved through evolution, and can be found from 
nematodes to humans. Over a dozen caspases have been identified in mammals; about 
two-thirds of them have been suggested to function in apoptosis (9) (Table1). 
 
Table 1. Caspases involving in apoptosis in mammals 
Modified from (6) 
 
Initiator Caspases Effector Caspases 
Caspase 2 Caspase 3 
Caspase 8 Caspase 6 




All known caspases possess an active-site cysteine, and cleave substrates after aspartic 
acid residues (10). A caspase's distinct substrate specificity is determined by the four 
residues amino-terminal to the cleavage site (11). Caspases have been divided into 
subfamilies based on their substrate preference, extent of sequence identity and structural 
similarities. Caspases can be thought of as the central executioners of the apoptotic 
pathway because they cause most of the morphological changes that differentiate 




through mutation or applying pharmacological inhibitors, will slow down or even prevent 
apoptosis (12). Thus, blocking caspases can increase cell survival.  
Activation of caspases does not result in the degradation of all of the cellular proteins. 
Rather, caspases selectively cleave a restricted set of target proteins, usually at one or 
more positions in the primary sequence and always after an aspartate residue. In most 
cases, caspase-mediated protein cleavage results in inactivation of the target protein, 
which can be either a single polypeptide chain enzymes, such as poly ADP-ribose 
polymerase, or a complex macromolecular network (4). Caspase-mediated cleavage of 
specific substrates explains several of the apoptotic morphological features. For example, 
cleavage of the nuclear lamins is required for nuclear shrinking and blebbing (13). 
However, caspases can also activate proteins, either directly, by cutting off a negative 
regulatory domain, or indirectly, by inactivating a regulatory subunit. Several important 
caspase substrates have been identified in recent years. One of the most exciting 
discoveries was the elucidation of the mechanism of activation of the nuclease 
responsible for nucleosomal degradation. Wyllie et. al. first described that nuclease cuts 
the genomic DNA between nucleosomes to generate DNA fragments of approximately 
180 base pairs. The presence of this DNA ladder has been used extensively as a marker 
for apoptotic cell death (14). Wang and Nagata showed that the DNA ladder nuclease 
(caspase-activated DNase, or CAD) is present in living cells prior to apoptosis as an 
inactive complex with an inhibitory subunit, called ICAD (15); caspase-3-mediated 
cleavage of ICAD activates CAD and causes the release and activation of the catalytic 
subunit (16).  
Since caspases activity plays very important role in apoptotic process, a proper 
understanding of apoptosis is required to understand how caspases are activated. Similar 
to other proteases, caspases are synthesized as an inactive pro-enzyme. Most caspases are 
activated by proteolytic cleavage of the pro-enzyme between the p20 and p10 domains. 
Interestingly, all these cleavage sites occur at Asp-x sites- candidate caspase substrate 
sites- suggesting the possibility of autocatalytic activation (17). Indeed, the simplest way 
to activate a pro-caspase is to expose it to another, previously activated caspase molecule 
(Fig.2). 
 
Figure 2. Mechanisms of caspases activation  
Mechanisms of caspase activation include (a) proteolytic cleavage by an upstream caspase, (b) 
induced proximity, and (c) holoenzyme formation. 
Adapted by permission from Macmillan Publishers Ltd: [Nature] (1), copyright (2000) 
This “caspase cascade” strategy of caspase activation is used extensively by cells to 
activate three short prodomain caspases, caspase-3, -6 and -7. These three downstream 
effector caspases are considered the most active members of the caspase family, and are 
usually more abundant than other ones. The caspase cascade is a useful method to 
amplify and integrate pro-apoptotic signals inside the cell. The entire caspase activation 
cascade is summarized in figure 3; effector caspases are usually activated by an upstream 
caspase, whereas initiator caspases are activated through regulated protein–protein 
interactions. The actual molecular mechanisms mediating initiator caspase activation are 





Figure 3. Order of caspase activation 
Caspase cascade results in Cytochrome C release from Mitochondria into the cytosol. 
 Modified from (4) 
1.3 Extrinsic apoptotic pathway 
The extrinsic or death receptor pathway is activated by extracellular ligands such as 
CD95L and tumor necrosis factor (TNF-α) that bind to death-receptor superfamily 
members such as CD95 and tumor necrosis factor receptor I and/or II (TNFRI, TNFRII). 
The CD95L /CD95 receptor and the TNFR/TNF-α are the most well-known initiators of 
the extrinsic pathway (12). Binding of these ligands to their receptors induce receptor 
clustering and formation of a death inducing signalling complex (Fig.4). This complex 
recruits pro-caspase-8 through the adaptor molecule FADD (Fas-associated death domain 
protein). Pro-caspase -8 activates caspase-8 which stimulates cleavage and activation of 
several different effector caspases. Caspase-8 activation can be blocked by recruitment of 








Figure 4. Two major apoptotic pathways in mammalian cells 
Adapted by permission from Macmillan Publishers Ltd: [Nature] (1), copyright (2000) 
 
1.4 Intrinsic apoptotic pathway 
 The intrinsic or mitochondrial apoptotic pathway is activated in response to either 
external or internal signals including DNA damage (18). In addition, this pathway can be 
activated when Cytochrome C is released from the intra-membrane space of the 
mitochondria into the cytosol (Fig.4). This release is under tight control by the BCL-2 







The Bcl-2 protein is usually attached to the intracellular membranes such as 
endoplasmic reticulum and mitochondria; however, some other members of this family 
such as Bax, Bad, and Bid proteins, can shuttle between the cytosol and organelles. The 
cytosolic forms of these proteins are inactive. Pro-apoptotic signals redirect these proteins 
to the mitochondria, where they are activated and initiate the destruction of the cell . 
The Bcl-2/Bax ratio indicates the relative amounts of anti- and pro-apoptotic proteins 
of the BCL-2 family. This ratio decrease in response to death signals such as DNA 
damage (through p53) or reactive oxygen species (19). Members of the BCL-2 family 
stimulate release of Cytochrome C and other proteins from the mitochondrial intra-
membrane space into the cytosol. Cytosolic Cytochrome C binds to apoptotic protease 
activating factor 1 (Apaf-1) which in turn stimulates binding to procaspase-9 to form a 
complex known as the apoptosome. When bound to the apoptosome, procaspase-9 is 
activated. Activated caspase-9 in the apoptosome activates the effector caspases 3, 6, and 
7 by cleavage of their respective pro-caspases (4) (Fig.4 and 3). 
The extrinsic and intrinsic apoptotic pathways meet each other at the level of caspase-
3 activation. Caspase-3 activity is inhibited by the inhibitors of apoptosis proteins (IAP), 
whose activity in turn can be antagonized by the Smac (second mitochondria-derived 
activator of caspases) or DIABLO (direct IAP binding protein with low pI) proteins 
released from mitochondria. Downstream of caspase-3, the apoptotic programme results 
to the cell death. 
Bid, which is a pro-apoptotic member of the BCL-2 family, provides the integration 
between two pathways. Activated caspase-8 mediates Bid cleavage to tBid and results in 
its translocation to mitochondria, where its pro-apoptotic activity promotes cytochrome C 
release by oligomerization to Bak and Bax proteins, other pro-apoptotic members of this 
family, and pore formation in mitochondrial membrane (20). Under most conditions, 
however, the death-receptor and mitochondrial pathways works independently with 





1.5 BCL-2 family and its role in apoptosis  
The B-cell CLL/lymphoma 2 (BCL-2) family of genes and proteins present a 
critical intracellular checkpoint of apoptosis. The members of this family are 
categorized into two main groups. The first group consists of the anti-apoptotic 
members that share a high degree of structural and functional similarities with Bcl-
2 protein, while the second one includes proteins that have fewer similarities to 
Bcl-2 and show pro-apoptotic activity. The second group is in turn divided into two 
subgroups, the Bcl-2-associated X protein (Bax)-like death factors and the BH3-
only proteins (Table 2). 
 
Table 2. The BCL-2 family of proteins in different organisms 
Modified from (4) 
 
Death function Organism Members Structure 
Anti-apoptotic Mammals Bcl-2,Bcl-XL, Mcl-1 BH Multi-domain 
 C.elegans CED-9 BH Multi-domain 
 Xenopus XRI, XRII BH Multi-domain 
    
Pro-apoptotic Mammals Bax, Bak, Bok BH Multi-domain 
  Bad, Bik, Bid BH3-Only 
 C.elegans EGL-1 BH3-Only 
 
Interestingly, this family of genes and their protein products are evolutionarily 
conserved and their structures have not been changed from nematodes to human. A 
number of viruses encode Bcl-2 homologs, including most gamma herpes viruses. Most 
of these viral homologs are anti-apoptotic, probably because viruses need to keep the 
infected cells alive for latent and persistent infection (21). One of the key features of the 
BCL-2 family proteins is that members of this family share sequence similarities in four 
BH (Bcl-2-homology region) domains—the BH1, 2, 3, and 4 domains—although not all 
of them poses all four domains (Fig.5). These domains correspond to a α-helical domain, 
which mutagenesis studies have indicated are important for the various molecular 
functions and for protein-protein interactions (homo and hetero dimerization) among this 
family. Furthermore, most of the members contain a hydrophobic carboxyterminal 




Figure 5. Schematic structure of BCL-2 family of proteins 
The anti-apoptotic proteins of BCL-2 family have more co-opted by other organisms. This group 
usually posses three to four BH regions. Alternatively, the pro-apoptotic proteins of this family are less 
conserved and usually do not contain the BH4 amino terminal domain. BH3 domain is the most common 
feature of all family members. 
Adapted by permission from Macmillan Publishers Ltd: [Nature] (1), copyright (2000) 
 
The BH1 and BH2 domains are necessary for the death-repression function of the anti-
apoptosis molecules, whereas the BH3 domain is required for the death-promotion 
function of the pro-apoptotic ones. In addition, the BH4 domain, which presents mainly 
in the anti-apoptotic molecules, is also important for death-inhibition functions (22, 23). 
It seems that the “BH3-only” molecules, such as Bid, Bik, and Bad, are sensors for the 
peripheral death signals and are able to activate the “multi-domain” executioner 
molecules, Bax or Bak (24). This process in some ways resembles the caspase cascade, in 
which the initiator caspases activate the effector caspases. 
 
1.6 Protein interactions among BCL-2 family members 
The BCL-2 family of proteins can interact with each other and also with several other 







its interaction with Bcl-2. Many other BCL-2 family proteins were also cloned based on 
this type of interaction. The most common type of interaction is between anti-death and 
pro-death members, such as Bcl-2 versus Bax. This interaction can result in antagonistic 
action of the two types of molecules and thus could control the death program (25). 
Interestingly, not all anti-death molecules can interact with all pro-death molecules. It 
seems that some members of one group will preferentially bind to some members of the 
other group. For example, the anti-death molecule Bcl-2 binds to Bax, but not to Bak 
(26), and these molecules may only antagonize the function of those molecules to which 
they bind. This type of selectivity suggests that specific amino acids required for 
particular interactions may only exist in some but not all of the family members. In 
addition, it may also suggest that in certain tissues and for certain death stimuli, a specific 
set of BCL-2 family proteins is critically involved. 
The second type of interaction occurs between two pro-death members, usually 
between a molecule with only one BH3 domain and a multi-domain molecule, such as 
Bad and Bik with Bax or Bak. Such interactions could be important for the activation of 
the multi-domain executioner molecules such as Bax or Bak (26).  
The third type of interaction is “multimerization” of the same molecule. This has been 
observed in both anti-death molecules, such as Bcl-2 or Bcl-XL , and pro-death 
molecules, such as Bax and Bak (24). The ability of Bax or Bak to oligomerize has been 
considered an important factor in their function to produce or open the mitochondrial 
channels in purpose of releasing mitochondrial apoptotic factors such as Cytochrome C 
(27) 
Overall, the relative ratio of pro-survival (Bcl-2-like) and pro-apoptotic (Bax-like and 
BH3 only) proteins seems to determine the cell sensitivity or resistance to the apoptotic 
stimuli.  
Further discussion about the genes that their relative expression levels were 




1.7 Death- inhibiting and promoting genes of BCL-2 family 
1.7.1 Anti-apoptotic Bcl-2  
Bcl-2 is a proto-oncogene that was identified at the chromosomal translocation 
breakpoint, between chromosomes 14 and 18, t (14; 18), in non-Hodgkin’s follicular B-
cell lymphomas. It promotes tumorogenesis by preventing cell death instead of increasing 
cell division rate as well as arresting cells in the Go/G1 phase of the cell cycle (4) . Based 
on this fact, Bcl-2 was classified as a new class of oncogenes. Protein product of 
indicated gene is 26 kDa consisting of 239 amino acids in human and contains a single 
highly hydrophobic domain at its C-terminus that helps the protein to localise mainly in 
the mitochondrial outer membrane. 
Bcl-2 gene expression was observed in a wide variety of foetal tissues, whereas it was 
claimed that this gene shows restricted expression in more rapidly proliferating and 
differentiating cells in adult tissues (28). Bcl-2 gene can be up-regulated by tumour 
suppressor P53 (29). 
The main role of Bcl-2 gene product in the process of apoptosis is based on its ability 
to inhibit ion conductive channels formation in mitochondrial membrane, and in most 
cases to prevent mitochondrial disruption and the release of Cytochrome C. Therfore, 
Bcl-2 protein can inhibit the following association of Cytochrome C with Apaf-1 and 
therefore suppress the activation of caspase-9 (4). Based on this scenario, two anti-
apoptotic roles are suggested for Bcl-2 protein which in one of them its activity is 
mitochondrial dependent and in the next one Bcl-2 may play a role in the inactivation of 
initiator caspases, such as caspase-2, that acts upstream or independently of Cytochrome 
C release and mitochondrial involvement (30). 
 
1.7.2 Anti-apoptotic Bcl-X 
BCL-2L1 (BCLX, BCL-2L, BCL-X). The BCL-2-like 1 (BCL-2L1) gene maps on 
chromosome 20q11.21 and consists of 3 exons and 2 introns, encoding a 233 amino acid 
protein, localised to the outer mitochondrial membrane. This gene undergoes alternative 




the Bcl-XL, Bcl-XS, and Bcl-Xγ. The large transcript Bcl-XL is pro-survival and mainly 
expresses in long-lived cells and localises in the mitochondrial membranes (31). 
Bcl-XL protein shows high similarities with Bcl-2 and contains the BH1 to BH4 
conserved domains as well as a hydrophobic region at its C-terminus. According to 
different crystallography reports, the BH1, BH2 and BH3 motifs of Bcl-XL are very 
close to each other, thus, forming a “hydrophobic pocket” through that the BH3 region of 
pro-apoptotic molecules interact with this protein (4). For example, the presence of an 
anti-apoptotic molecule, such as Bcl-2 or Bcl-XL, can inhibit the activation of the pro-
apoptotic Bax. Therefore, Bcl-XL, like the Bcl-2 protein, regulates programmed cell 
death by interaction and blocking the death-promoter proteins. Minn et. al., in 1997, 
suggested that Bcl-XL may regulate survival by regulating the permeability of the 
intracellular membranes, preventing the removal of the Cytochrome C in cytosol, and 
taking care of the membrane integrity (32). On the other hand, it has been reported that 
Bcl-XL can bind to Apaf-1, like the Bcl-2 function, and then form a complex that 
prevents the activation of caspase-9 (33).  
The Bcl-XL gene is transcriptionally reactive (34). Its expression is up-regulated by 
irradiation (35), and insulin-like growth factor-1 (IGF-1) (6, 36, 37).  
1.7.3 Pro-apoptotic Bax   
Apte et. al. in 1995 applying somatic cell hybrid and in situ hybridization showed that 
the human Bax gene is located on chromosome 19q13.3–q13.4 (36).This gene consists of 
6 exons and 5 introns that encode a 21 kDa protein contains the three conserved regions 
BH1, BH2 and BH3, very similar to Bcl-2 structure, which provide the susceptibility to 
form hetero-dimers with Bcl-2 and imply its death promoting function (35). The 
formation of hetero-dimers between Bax and the other members of the BCL-2 family 
play important role in the regulation of cell death scenario (4).  
It seems that the tumour suppressor P53 can transcriptionally regulate Bax expression.  
Actually, in vitro experiments have shown that P53 up-regulates the Bax gene, while in 
vivo studies using P53 -/- mice have indicated the opposite results (37) . 
Bax is the first death-promoting member of the BCL-2 family to be identified, and it 




healthy cells Bax protein is localized in cytosol in monomeric conformation, after 
exposure to a death signal, this protein translocates to the mitochondria and 
homodimerizes with another Bax or heterodimerizes with other pro-apoptotic members 
such as Bak protein (38). 
The presence of anti-apoptotic molecules such as Bcl-2 and Bcl-XL, can inhibit the 
activation of Bax following a death signal (39). However, the death promoting function 
of Bax is not associated with its ability to interact with these molecules. Bax mediates 
apoptosis through a mitochondrial-mediated pathway that can be either caspase-
associated or not, with the caspase-dependent mitochondrial pathway being based on the 
release of cytochrome C from the mitochondrial membranes (4, 35).  
Bax is an important gene for the control of cell death. Cells that over express this gene 
show enhanced apoptosis, whereas Bax-null cells are resistant to apoptosis (25). Bax 
expression has also been associated with tumour development (35). 
1.7.4 Pro-apoptotic Bak 
Bcl-2 homologous antagonist/killer 1 (Bak1) has been cloned as a Bcl-2-related gene, 
which consists of 6 exons and maps to chromosome 6p21.3 on the human genome,(40), 
encoding a 211-amino acid protein with a relative molecular weight of 23400 (41). Bak 
gene product is very similar to Bax protein structurally and functionally. This protein 
contains the conserved domains BH1 to BH3 and enhances apoptotic cell death  (25).  
The widespread tissue distribution of Bak messenger RNA suggests that cell-death-
inducing activity is broadly distributed, and tissue-specific modulation of apoptosis is 
controlled primarily by regulation of molecules that inhibit apoptosis (6). Furthermore, 
Leu et. al. in 2004 demonstrated that Bak is regulated at the transcriptional level, with 
over expression of P53 (42). The anti-apoptotic Bcl-XL interacts with Bak and inhibits its 
activity (43).   
1.7.5 Pro-apoptotic Bad 
Bad or Bcl-XL/Bcl-2-associated death promoter is a death-promoting member of the 
BCL-2 family that was initially detected because of its ability to interact with the anti-




protein product is about 168 amino acids. The interesting fact about Bad protein is this 
protein neither hetero-dimerizes with other members of the family, such as pro-apoptotic 
Bax, nor homodimerizes. Bad forms an inactivating dimer with Bcl-XL, but doesn’t have 
any effect on the anti-apoptotic activity of Bcl-2  because this protein only has the BH3 
domain, which is essential for its heterodimerization with the other family members, and 
slight similarity with Bcl-2 (6, 44). Kaipia et. al. in 1997  indicated that the Bad protein 
shows a wide tissue distribution with  higher expression levels in lung, ovary, uterus and 
brain (45). It seems that the active form of Bad, which bound to Bcl-2 and Bcl-XL in the 
mitochondria, is the dephosphorylated form, while some factors such as IGF-1 inactivates 
this protein through phosphorilation (6, 25). It has been suggested that Bad mediates 
apoptosis through a caspase-dependent pathway, since the cell death could be inhibited in 
granulosa cells, which already had shown apoptosis because of over expression of Bad 
mRNA, using a caspase inhibitor (45). Therefore, the association of Bad/Bcl-2/Bcl-XL 
results in the release of Cytochrome C, which in turn, activates the proteolytic caspase-
mediated cascade (25). 
 
1.7.6 Pro-apoptotic Bik 
The Bik gene maps on chromosome 22q13.3 and translates to a 19kb protein with 5 
exons and 4 introns (46).It has been demonstrated applying Northern blot analysis that 
Bik gene expression is elevated in heart and skeletal muscle (46) and restricted in kidney, 
pancreas, lung, liver, prostate and testis (6).  
Although the protein heterodimerizes with anti-apoptotic molecules, it has been found 
that this interaction is not sufficient to cause death.  It has been reported that the 
heterodimerization with death-inhibiting proteins such as Bcl-2 and Bcl-XL is not enough 
for the death-promoting effect of the complex. Mutation analysis by deletion of the BH3 
domain showed that the pro-apoptotic activity is present even in the absence of the 
heterodimerizationion (6). This fact shows that Bik protein mediates apoptosis through a 
mechanism which is not dependent on its dimerization. Bik also may be rapidly turned 





1.8 BCL-2 family of genes in colon cancer 
1.8.1 Apoptosis in Colon 
Cancerous cells have some characteristics that are not present in their normal 
counterparts. Normal cells, for example, are subject to internal and external inhibitory 
signals, which are lost during carcinogenesis. A decreased rate of cell death is as 
important as increased proliferation in determining the probability of a cell changing to a 
pre-cancerous state. When normal cells differentiate they divide slowly, but cancerous 
cells use the “dedifferentiation trick” to increase their growth rate. Also, they loosen their 
contact with other cells or with the extracellular matrix to escape from growth inhibition. 
 In colonic epithelium keeping a constant number of cells is critical. The high 
incidence of colon cancer makes understanding of the balance between cell proliferation 
and apoptosis even more important. Histologically, colon tissue is made up of four 
distinct layers of mucosa and muscle, the most inner layer of the mucosa is the colonic 
epithelium and contains invaginations known as crypts (48). Cell proliferation, migration, 
differentiation and apoptosis are organized along the crypt axis. Normal colonic crypts 
are composed of four distinct layers which include stem cells at the base, a proliferation 
and a differentiation zone in the lower third of the crypt, a migration zone in the upper 
two-thirds, and the surface epithelium where old cells will be eliminated by apoptosis, 
respectively (49). 
Newly produced colonic epithelial cells migrate from the base of the crypt to the 
surface epithelium within 6–7 days. The normal construction of the crypt is maintained 
by a balance between cell proliferation in the bottom and apoptosis at the top of the crypt 
and surface epithelium (50). In 1998 Lengauer and Vogelstein showed that increased 
proliferation and decreased apoptosis were the main features present in neoplastic colon. 
In addition, malignant neoplasms are the consequence of activation and/or suppression of 
regulatory genes that control cell proliferation and apoptosis (51). The accumulation of 
mutations in these genes is common and produces the malignant nature of neoplasm. In 
normal colonic crypts, cycling cells may undergo mutations during their migration along 




functions properly at the surface epithelium (50). However, some mutations may cause 
resistance to apoptosis thus leading to tumorogenesis.  
Since colorectal cancer remains the third most frequent fatal cancer in the western 
world and most sporadic cases of colon cancers go through progressive stage (52), 
keeping the balance between cell proliferation and apoptosis and also assessing the 
expression levels of the regulatory genes and proteins is very important.  
1.8.2 The role of BCL-2 family and mitochondrial apoptotic pathway 
in colon cancer progression 
Apoptosis inhibition plays critical role in tumorogenesis. Cell death regulating genes 
and proteins seem to be good candidates for molecular cancer therapy and among them, 
the members of BCL-2 family are prominent targets. Deregulation of BCL-2 family 
members has been tightly linked to tumorogenesis (53). All the anti-apoptotic members 
seem to function as oncogenes, and pro-apoptotic ones can act as tumour suppressors. 
This is supported by a comparative genomic hybridization (CGH) database search for 
copy number gains and/or deletions of chromosomal loci of members of the BCL-2 
family. This indicated specific roles for these genes and their pro- and anti-apoptotic 
products during the pathogenesis of tumours (6). Every pro- and anti-apoptotic members 
of the BCL-2 family plays specific roles in cancer development. For example, Bcl-2 gene 
was found to be over-expressed in some types of human tumors such as colon, gastric, 
lung, and breast cancer (6). In some cases, such as lung and breast cancers, Bcl-2  up-
regulation can be used as a prognostic marker (54, 55), while in other types, it is still 
under investigation. Huang et. al. in 2002 showed that in some cells, such as lymphoma 
cells, the phosphorylation/ dephosphorylation of the Bcl-2 protein plays an important role 
in apoptosis, and therefore, can be involved in carcinogenesis (56). Researchers applying 
immunohistochemical methods showed that the Bcl-XL protein is widely expressed in 
different types of cancer cells such as colon, breast and ovarian cancers and over-
expression of the Bcl-XL gene can promote tumor formation in mice. Also Bcl-XL 
expression is induced by a wide range of survival signals (57).In opposite, in another 
study it was shown that the Bcl-XL gene can be down-regulated in colon cancer, which 




hyperphosphorylated in colorectal and other types of cancers as well as different 
malignant cell lines, heterodimerization of Bad and Bcl-2 would decreased in this 
situation (59), which consequently reduce the pro-apoptotic activity of this protein. This 
result was confirmed four years later, when it was shown that the phosphorylated form of 
Bad protein cannot prevent tissues from excessive growth (6) since the phosphorylated 
form of this protein in inactive. 
In healthy cells, Bax contributes to tissue homeostasis through the induction of 
apoptosis to remove of excessive and damaged cells. However, in cancer cells the 
concentration of this protein is reduced, which in some cases is accompanied by mutation 
in the P53 tumor suppressor gene (25). Indeed, currently, the potent tumour-suppressing 
activity of this protein is used for therapeutic purposes (60). Based on 
immunohistochemical studies it has been shown that Bak expression is altered in 
cancerous cells. In colorectal carcinomas, for instance, the increased levels of Bak and 
Bcl-2 heterodimerization contribute to tumour growth (59). In normal gastrointestinal 
epithelial tissues, expression of  Bak gene is up-regulated during differentiation, which is 
essential for normal cell turnover, whereas in gastric tumours Bak level is down-regulated 
compared to the normal mucosa . Down regulation of the Bak gene could perhaps be 
explained by missense mutations in the Bak gene (61). It was explained previously that in 
many of colorectal and breast tumours the Bik gene expression is lost due to up-stream 
silencing mutations, therefore the absence of this gene is implicated in development of 
these cancer types (6). Moreover, in 2002 it was suggested that since certain 
chemotherapeutic agents induce pro-apoptotic Bik protein over-expression and sensitize 
tumour cells to apoptosis this protein could be applied as a potential therapeutic target for 
human cancer (62). 
 
Colon tumors are developed from a serious of somatic mutations subsequent to an 
initiation event such as DNA methylation. Experimental carcinogens that are known to 
induce gastrointestinal tumors in rodents such as 1,2-dimethylhydrazin and its derivative 
azoxymethane (AOM) are mostly methylating agents. These chemical agents were 
documented not only as gastrointestinal carcinogens, also as causes of other cancers for 




hepatic steatosis, DNA damage removal either through repair systems or apoptosis is 
critical in these disorders. Previously, it was described that after carcinogen injection and 
during the initial phases of tumorogenesis, there is an immediate apoptotic response to 
DNA damage in colon epithelium (64). One year later, the same research group indicated 
that the regulation of apoptosis-related protein Bcl-2, Bcl-XL, and Bax was altered in 
AOM induced colonic neoplastic tissue in Sprague Dawley rats, while no significant 
difference was found between the expression of these proteins in the non-neoplastic 
mucosa of the AOM treated rats and normal mucosa of saline treated control group (65). 
These results show that apoptotic gene and/or protein expressions in early initiation phase 
would be different from late phase of AOM induced colon tumorogenesis. However, 






1.9 BCL-2 family of genes in liver disease 
Non-alcoholic fatty liver disease or NAFLD is a disease of our generation as it was 
mostly unrecognized before 1980 and was not taken seriously until the past few years.  In 
fact, this disease was recognised after the industrial revolution, when individual lifestyles 
were changed. Since NAFLD has roots in lifestyles and is related to obesity, physical 
activity and diabetes, it is now accepted as a metabolic disorder. This section will discuss 
liver tissue and its function as well as hepatic steatosis and its consequent problems, 
including the role of apoptosis in the progression of liver disease. 
1.9.1 Liver tissue and obesity related disease 
Liver represents about 2% of the total body weight. Liver function is comparable to 
the function of stomach, intestine, pancreas and kidney together. In fact, all digested 
foods are taken up by the intestine and then by the liver, which then stores the energy 
derived from the oxidation of the nutrients. Therefore, liver is the power source of the 
body. Liver is responsible for important functions such as energy storage, metabolism, 
production and secretion of the serum proteins, as well as processing of absorbed 
nutrients, bile acid synthesis and bile formation. Although the liver is made up of several 
cell populations, the most abundant cell type by mass and by number is the hepatocyte. 
Hepatocytes play role in maintenance of glucose, amino acid, ammonia and bicarbonate 
homeostasis in body, as well as the storage and processing of signal molecules (66). 
Therefore, keeping the well-organized physiological function of hepatocytes is very 
critical. Steotasis is described as fatty liver and characterized by fat droplet accumulation 
in hepatocytes  (67). 
In 1980, Ludwig and his colleagues defined the term of nonalcoholic steatohepatitis 
(NASH) as a form of liver injury that was very similar to alcoholic hepatitis but was 
noticed in obese, diabetic patients, who denied alcohol use . Nonalcoholic steatohepatitis 
or NASH is a kind of metabolic liver disease in which fatty change or steatosis is 
associated with inflammation, hepatocyte injury and/or hepatic fibrosis. This problem, in 
fact, is the advanced stage of non-alcoholic fatty liver disease or NAFLD which is a liver 
syndrome that describes a range of liver abnormalities from simple triglyceride 
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accumulation in hepatocytes (hepatic steatosis) to some more dangerous pathologic cases 
such as steatohepatitis, progressive liver fibrosis and even hepatocellular carcinoma  (68). 
There are multiple factors that have been associated with NAFLD and NASH such as 
obesity, diabetes type 2, insulin resistance and hyperinsulenemia, hyperlipidemia, 
lifestyle and lack of physical activity (69). Among all of them, obesity and insulin 
resistance are the most important promoting factors. The majority of patients with 
NAFLD do not show any symptom of their disease initially, but later hepatomegaly is the 
first common physical sign (70). Correction of insulin resistance by diet and increased 
physical activity is a logical approach to prevent early NASH. 
According to previous studies, hepatic steatosis is a pre-requisite for events that lead 
to liver injury; however, the mechanisms by which hepatic steatosis progress to 
NASH/NAFLD is poorly understood (71). A growing body of evidence suggests that 
increased programmed cell death in hepatocytes plays an important, if not critical, role in 
liver disease progression (72).  
1.9.2 Apoptosis in Hepatocytes 
 
More frequent hepatocyte death has been increasingly noticed as an intermediate step 
between liver injury and fibrosis (73). Studies using a genetic model of NAFLD, obese 
(ob/ob) mice, that are deficient in leptin, have shown a significantly increased expression 
of some apoptotic mediators such as TNF-α and cytochrome P4502E1 (CYP2E1) mRNA, 
and oxidative stress (74). Also, it was explained previously that obese patients with 
NASH have enhanced expression of TNF-α mRNA, whereas obese patients without 
NASH do not (75), which shows that obese individuals are probably more prone to 
extrinsic apoptosis pathway.  In vitro exposure of human hepatocytes to long chain 
saturated free fatty acids results in a “dose dependent” induction of apoptosis (76). As 
previously described by Canbay et. al., death receptor-mediated apoptosis is particularly 
prominent in the liver (77). In 2004, Takehara and collaborators showed that disruption 
of Bcl-XL expression in hepatocytes can lead to continuous apoptosis of these cells and 
result in liver disorders (72). Another study has demonstrated that hepatocyte apoptosis 
and Fas protein expression are up regulated in patients with NASH disorder (78). In vitro 
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studies using a liver cancer cell line have revealed that free fatty acids also promote up-
regulation of the death receptor (79) as well as redistribution of pro apoptotic Bax protein 
from cytosol to lysosome that in turn induces mitochondrial membrane channel formation 
(80), releasing Cytochrome C in to the cytosol and activation of caspases-3 and -7, and 
thus cell death machinery.  
 
1.10 Animal model of obesity 
The fa mutation on Fatty (Fa) gene, which is located on chromosome 5 in rats, for the 
first time was discovered in 1961 by Zucker and results in non-functional leptin receptor 
(81). Homozygote animals (fa/fa) become noticeably obese by three to five weeks of age 
compare to their heterozygote (Fa/fa) or homozygote (Fa/Fa) lean counterparts. The 
Zucker (fa/fa) rats are the best-known and most widely used rat model of obesity that has 
been extensively used for investigations of obesity-associated diseases. The obesity in 
these animals is inherited as a Mendelian recessive trait. Obese animals suffer from 
hyper-lipemia, hypercholesterolemia (82), as well as hyper-insulinemia (83). Leptin 
hormone is produced by adipose tissues and is responsible for regulating fat metabolism 
and control body weight by signalling the hypothalamus to suppress appetite (Guyton et. 
al., 2000). Non-functional leptin receptor in (fa/fa) Zucker rats results in uncontrolled 
appetite and become morbidly obese. 
 
 
Figure 6. Lean and obese Zucker rats 
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Seven-week-old Lean (Fa/?) Zucker rats with functional leptin receptor (left) and 
Obese (fa/fa) Zucker rats with non-functional leptin receptor (right). 
1.11 Objectives of current study 
The objective of this study was to investigate the differences between pro- and anti-
apoptotic gene expression levels in liver and colon tissues of obese and lean individuals 
to investigate whether or not the BCL-2 family of genes play role in the obesity effected 
progression of hepatic steatosis and colon cancer.   
The specific goals of this study were,  
1) To compare pro- and anti-apoptotic gene expression levels in hepatic tissue and 
colonic mucosa in obese rats versus lean rats, 
2) To compare the reaction of obese and lean animals to azoxymethane (AOM) 
induced apoptosis,  
3) To determine if the effect of obesity on colon cancer and hepatic steatosis could be 
predicted by an analysis of apoptotic gene expressions during the first 24 hours post 
administration of the carcinogen AOM. 
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Chapter 2 Materials and Methods 
 
2.1  Animal care 
 Seven week old female Obese (fa/fa) rats (n=30) and their lean (Fa/?) counterparts 
(n=30) were purchased from Charles River Laboratory (Wilmington, MA, USA) and 
housed in suspended wire cages approximately 10 cm above a sawdust bedding tray with 
a 12h light/12h dark cycle, in the animal housing facility, Department of Biology, 
University of Waterloo. Temperature and relative humidity were controlled at 22˚C and 
55% respectively. All animals were handled in the above conditions for 10 days with free 
access to standard laboratory rodent chow and drinking water until initiation of the 
experiment. All animals were cared according to the guidelines of the Canadian Council 
on Animal Care and the protocol was approved by the University of Waterloo Animal 
Care committee.   
Both groups of animals were randomly weighed and the average weight of lean and 
obese animals was 111.07±9.0g and 182.4±8.4g, respectively, values with 95% 
confidence interval. 
 
2.2 Body Weights, AOM Injection and Termination  
At eight weeks of age, obese and lean rats were randomly weighed again and the 
average weights of lean and obese animals were 148±8.5g and 268±11.4g, respectively.  
Ten days after accommodation, all animals, except the control group, were injected 
with colon specific carcinogen Azoxymethane (AOM) at the doses of 10mg/Kg body 
weight.  Obese animals and their lean counterparts were then randomly divided into four 
groups. Group 1 (n=6) was a non-injected control group, Group 2 (n=8) was terminated 
3h after injection of AOM, Group 3 (n=8) was terminated 9h after injection of AOM, and 
Group 4 (n=8) were terminated 24h after injection of AOM (Figure 2). After the 






















Figure 7. Schematic representation of the experimental design 
 
Liver and distal colon mucosa was removed rapidly, gross anatomies of indicated 
tissues were observed and any pathologic abnormalities were recorded. Samples were 
then transferred to RNAlater™ stabilizer solution (Sigma, Canada), snap-frozen in dry 
ice and stored in -80⁰C. Weights of liver as well as other tissues such as kidney, spleen, 
and heart were recorded and these samples were also frozen for future research.  
2.3 Preparation of Total RNA from Zucker Rat Liver and Colon 
Mucosa 
Analysis of RNA levels is a method for gene expression studies. Isolation of total 
RNA of full-length is the first and may be the most critical step in analyzing RNA levels. 
Total RNA from eukaryotic RNA contains primarily ribosomal RNA (rRNA) and 
transfer RNA (rRNA) and in a much lower amount messenger RNA (mRNA).  In this 
study, total RNA was extracted from liver and colon mucosa samples using a GE 
Healthcare RNAspin mini RNA isolation kit (http://www.gehealthcare.com/lifescience), 
according to the manufacturer’s direction. 
15mg of liver and 25mg of colon tissue (scraped mucosa) were sliced over dry ice (to 
keep tissues frozen) and submerged in to 350μl of ice-cold RA1 (buffer) and 3.5μl β-
mercaptoethanol, and then homogenized on ice using PT2100 Polytron homogenizer. The 
mixture was vortexed vigorously and transferred into RNAspin Mini filter units held in 2 
ml collection tubes and centrifuged at 13,200 rpm for 1 min in order to reduce the 
viscosity and clear the lysate. An equal volume of 70 % cold ethanol was added to the 
homogenized lysate and mixed via pipetting to adjust the RNA binding conditions, 
followed by filtration using the RNAspin mini column held in 2 ml collection tubes and 
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centrifuged at 10,000 rpm for 30 sec. The flow through was discarded and 350 µl of 
membrane desalting buffer was added to the RNeasy column, followed by a 1min 13,200 
rpm centrifugation in order to desalt the filter. The DNase reaction mixture was prepared 
in a sterile microcentrifuge tube, for each isolation 10ul reconstituted DNaseI and 90μl 
DNase reaction buffer was added exactly to the centre of the silica membrane of column 
and incubated for 15min at room temperature. After the incubation time, DNase enzyme 
was inactivated by 200ul RA2 buffer and centrifuged at 13200rpm for 1min. The RNeasy 
column was transferred to a new 2 ml collection tube and washed by 600ul RA3 buffer 
containing 96-100% Ethanol and centrifuged for 1min at 13200rpm.  The supernatant 
was discarded and another 250 µl Buffer RA3 was added and centrifuged for 2 min at 
13,200 rpm. The RNeasy column was again transferred to a new 2 ml collection tube and 
centrifuged for 1min at 13200rpm.  The RNeasy column was then transferred to a new 
1.5 ml RNase, DNase, proteinase free microcentrifuge tubes. RNA was eluted by two 
40μl RNase free water, followed by centrifugation at 13,200 rpm for 1 min each. RNA 
was stored at -80˚C. All the centrifuge steps were performed at 4˚C. 
 
2.4  RNA Quantification 
The quantity of extracted RNA samples was measured using a NanoDrop ND-1000 
UV is Spectrophotometer (NanoDrop Technologies). RNA concentration and purity was 
determined by measuring the ratio of the UV absorbance at 260nm and 280nm. 
Individual samples were measured in triplicate and the average was taken. The ratio of 
OD260nm/ OD280nm lower that 2 was considered as protein free RNA samples. 
  
2.5 cDNA Synthesis 
cDNA was synthesized from 1ug and 500ng of the total RNA from liver and colon 
mucosa, respectively¸ using the BIO-RAD iScript cDNA synthesis kit (Bio-Rad 
Laboratories, Canada) following the manufacturers direction applying 2ul oligo(dT) 
primer and Nuclease free water to the total volume of 15ul. Then, samples were 
incubated for 5min at 65˚C followed by snap chilling on ice for about 1min. 4ul of 5X 
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reaction mixture and 1ul of reverse transcriptase were added followed by 80min 
incubation at 42˚C in order to cDNA synthesises reaction, 5min at 85˚C to inactivate the 
enzyme and then store the cDNA product at -20˚C . All the above steps were performed 
on ice and a nuclease free bench. 
 
 
2.6 Primer Design 
Primers were designed based on the genomic and mRNA sequences retrieved from 
gene sequence databases such as National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/). The location of every intron and exon was determined 
within the gene sequences based on the mRNA sequence in order to design the primers at 
exon-exon junctions to avoid the false positive results arising from amplification of 
possible contaminating genomic DNA. Primers were checked by BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure that they did not have any non-specific 
binding sites on either the same gene or similar sequence sites in other species.  
 
2.7  Gradient PCR 
Gradient PCR was performed using GoTaq Green Master Mix (Promega, Madison, 
US) in order to set up the optimum annealing temperature for each separate gene. A 25μl 
PCR reaction was set up as follows: 12.5ul of 2X GoTaq Green Master Mix, which 
contains GoTaq® DNA Polymerase that is supplied in 2X Green GoTaq® Reaction Buffer 
(pH 8.5), 400μM dATP, 400μM dGTP, 400μM dCTP, 400μM dTTP and 3mM MgCl2; 
400nM of 10uM forward and reverse primers, 200ng cDNA template, and appropriate 
volume of nuclease free water was added to a 0.2ml nuclease free PCR tubes and 
centrifuged for 10sec. The thermal cycler was adjusted as follows: initial denaturation 
step at 95°C for 2min, subsequent denaturation step at 95°C for 30s, optimization of  the 
annealing conditions by performing the gradient reaction starting approximately 5°C 
below the calculated melting temperature of the primers and increasing the temperature in 
increments of 3°C to the annealing temperature for 30sec, followed by 72°C for 25sec for 
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template extension and a final extension of 5 minutes at 72°C, following a 4°C  
incubation for 10min. All the PCR reaction preparation steps were performed on ice. 
 
2.8 Agarose Gel Electrophoresis 
The GoTaq® Reaction Buffer contains yellow and blue dyes, the blue dye migrates at 
the same rate as 3–5kb DNA fragments, and the yellow dye migrates at a rate faster than 
primers (<50bp), in a 1% agarose gel. 
The PCR product was separated on 2% agarose gel containing 0.1% ethidium bromide 
(EtBr) and the DNA bands were visualized with a UV transilluminator containing an 
EtBr filter. The image system was a Fluorochem 8000 imager, which used Alpha 
Innotech (San Leandro, CA, USA) visible imaging software. The primer sequences and 
appropriate annealing temperatures are shown in the following Table. 
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Function Forward Primer Reverse Primer 
Bax NC_005100 
Bcl-2-related gene; involved in the 





an anti-apoptotic protein; involved in 
inhibiting cell death in many different cell 
types 
5′ GCTGGGATGCCTTTGTGGAA 3′ 5′ CTCACTTGTGGCCCAGGTA 3′ 
P53  multifunctional 
 
5′ GGAGAATATTTCACCCTTAAGATCC 3′ 
5′ GAGTGAGCCCTGCTGTCTCCT 3′ 
Bak1 NC_005119 BCL-2-antagonist/killer 1 5′ GTCCCTAGAACCCAACAGTGTCTT 3′ 5′ CTTAAATAGGCTGGAGGCGAT 3′ 
Bik NC_005106 
may be involved in differentiation of 
Oligodendroglial lineage cells 
5’TGGGATTGCTATGCACAGACTTG3’ 5’ TCAGGTGACACCCAGGCGC3’ 
Bad NC_005100 
may be involved in induction of 
programmed cell death 
5’CCAGCAGCCCAGAGTATGTTCC3’ 5’CATAGTCCCAGCGCCTCCA3’ 
Bcl-2l1 NC_005102 Also known as Bclx; Bcl-2l; bcl-X; Bcl-XL 5′ CTATCTTGGCTTTGGATCCTGGA 3′ 5′ CTCCCGGTTGCTCTGAGACAT 3′ 
Beta Actin J00691 Housekeeping gene 5′ CGTGCGTGACATTAAAGAGAA 3′ 5′ CGCTCATTGCCGATAGTGAT 3′ 
18srRNA   Housekeeping gene 5′ CCTACTTGGATAACTGTGGTA 3′ 5′ GTTATCTAGAGTCACCAAAGC 3′ 
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2.9 Real-Time PCR set up 
Real time detection of the PCR product was performed with the inclusion of the PCR 
reaction mixture with SYBR Green fluorescent dye. BioRad Real-Time thermal cycler 
machine equipped with fluorescence detector cameras was used to monitor the 
accumulation of the amplified product in each cycle.  
 
The same amount of tissue (15mg of liver and 25mg of colon tissue) was used for 
RNA extraction. Then the same amount of RNA (1ug and 500ng of the total RNA from 
liver and colon mucosa, respectively) was used to synthesize the cDNA. Finally, the 
expression of a reference gene, β-actin or 18srRNA housekeeping genes, was chosen to 
normalize and control for any difference in the cDNA input amount and pipeting errors. 
2.9.1 Standard curve creation 
The accuracy of PCR reaction for each individual gene was verified using standard 
curve analysis and Ct values. For this purpose, 10-fold cDNA serial dilutions was 
prepared and 2ul of each dilution was mixed with 30μl of 2X iQ SYBR Green Supermix, 
which contains 100 mM KCl, 40 mM Tris-HCI, pH 8.4, 0.4 mM of each dNTP (dATP, 
dCTP, dGTP, and dTTP), iTaq DNA polymerase 50 units/ml, 6 mM MgCl2, SYBR 
Green I, 20 nM fluoresein, and stabilizers; 6ul of cDNA sample. Appropriate final 
concentrations of cDNA template as well as particular primers were measured by 
performing a PCR reaction for each individual gene using primer concentration gradient 
variable between 300 to 100nM. Results of these reactions were summarized in table 4. 
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Table 4. Appropriate concentrations of designed primers 
Primer Name Primer Concentration 
Bax 150nM 






Beta Actin 100nM 
18srRNA  150nM 
    
Following primer addition, appropriate volume of nuclease free water was added to a 
0.2ml nuclease free microcentrifuge tubes to the final volume of 60μl, centrifuged for 
10sec and aliquot as 20ul in each well of an ice-cold 96well PCR plates. PCR plates were 
then centrifuged for 1min at 4˚C. All the above steps were performed on ice and a 
nuclease free bench. The iQ5 iCycler PCR system from BOI-RAD Real-Time system was 
set up at 95°C for 3min for the initial denaturation step, at 95°C for 30s for the 
subsequent denaturation step, the annealing temperature that was variable for each 
individual gene (refer to table 3) for 30s, followed by 72°C for 20s for template extension 
and a final extension step for 3 minutes at 72°C. The PCR efficiency was calculated 
applying the following formula 
 
E = 10 - (1/ slope) 
% Efficiency = 100 (E-1) 
PCR reactions with efficiency between 95% and 105% were accepted; otherwise the 
PCR reaction for that specific gene was performed again with different primer 
concentration and annealing temperature. 
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2.9.2 Melt curve analysis 
The melt curve analysis was performed for each separate gene to prove the accuracy 
of primers and show the possible genomic DNA contamination. In order to perform the 
Real-Time RT-PCR reactions, all the cDNA samples were diluted 10 times using 1X 
sterile, nuclease free TE buffer (10mM Tris with pH 8.0 and 0.1mM EDTA) from Roche 
Applied Science (http://www.roche-applied-science.com ).  PCR reaction was carried out 
using the BIO-RAD iQ SYBR Green 2step RT-PCR kit (Bio-Rad Laboratories, Canada) 
in 60μl volume consisting of 30μl of 2X iQ SYBR Green Supermix, 6μl of diluted cDNA 
sample, certain concentration of up- and down-stream primers, which was variable for 
each individual gene as described in previous section,  and appropriate volume of 
nuclease free water was added to a 0.2ml nuclease free microcentrifuge tubes, centrifuged 
for 10sec and dispensed as 20μl in each well of a  ice-cold 96well PCR plates. PCR plates 
were then centrifuged for 1min at 4˚C. All the above steps were performed on ice and a 
nuclease free bench. cDNA samples were amplified performing the following conditions: 
95˚C for 3min to activate the enzyme followed by 40 cycles of 95˚C for10s to denature, 
appropriate annealing temperature for each individual gene for 30s, and 72˚C for 20s to 
extend the template samples, with a final extension step for 3min at 72˚C; and melt curve 
creation step which was adjusted for each gene separately started at 5˚C above the 
annealing temperature and ended at 95˚C with 1˚C increment/cycle and hold 10s/cycle.   
 
2.10 Real-Time PCR Results Analysis 
The two most commonly used methods to analyze data from real-time, quantitative 
PCR experiments are absolute quantification and relative quantification. Absolute 
quantification determines the input copy number, usually by relating the PCR signal to a 
standard curve. Relative quantification relates the PCR signal of the target transcript in a 
treatment group to that of another sample such as an untreated control. The 2-ΔΔCt 
method, which for the first time in 2001 was proposed by Livak, is a reliable method to 
analyze the relative changes in gene expression from real-time quantitative PCR 
experiments. In the present study, this analysis method was applied for the first objective 
to find out the differential gene expression levels in non-injected obese animals relative to 
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their lean counterparts, and for the second objective, injected obese and lean animals 
relative to the non-injected control groups. PCR reaction was performed for each 
individual sample in triplicate and the average of Ct values was taken.  
 
ΔCt (Control) = Ct Target gene – Ct Reference gene 
ΔCt (Test) = Ct Target gene – Ct Reference gene 
ΔΔCt = ΔCt (Test) – ΔCt (Control) 
Relative fold change = 2-ΔΔCt 
 
 
2.11 Statistical Analysis 
 
The average of the relative expression level of mRNA of each individual tested group 
was taken and plotted a bar graph using Microsoft Excel. The standard deviations and the 
error bars were also calculated and added on the graph. Statistical analysis of the data was 
carried out using SPSS statistical software (SPSS Inc., Chicago, IL, USA). A comparison 
between lean and obese groups was performed and differences were determined using 
independent samples t-test, at a significance level of P <0 .05. Also, a comparison 
between the overall effect of DNA damage induction in obese and lean tested groups at 
different time points post AOM administration was performed using the one-way 
ANOVA test in conjugation with Tukey’s post hoc test, and the overall comparison 
between pro- and anti-apoptotic gene expression levels in liver and colon tissues within 
24 hours post AOM injection was carried out using two-way ANOVA test followed by a 
Tukey’s post hoc test and for all tests, p≤0.05 was considered significant. 
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Chapter 3 Results 
 
3.1   Animal weights  
As described in the previous chapter, three days after arrival and acclimatization, a 
subset of seven-week-old obese and lean Zucker rats were weighed and the average 
weight of these animals was 111.07±9.0 g for lean and 182.4±8.4 g for obese group. One 
week later the same animals were weighed again and the average weights of lean and 
obese animals were 148±8.5 g and 268±11.4 g, respectively. It was previously described 
that obese Zucker rats usually start to show overweight compare to lean animals at three 
to five weeks of age. This demonstrates that the body mass of obese rats used in this 







Figure 8. Lean and obese animals’ body mass at the age of seven and eight weeks 
Bar graphs indicate the average of animal body weight in each group ± S.E.M. at 
the age of seven and eight weeks; the asterisk (*) on the obese groups indicates that 
they have a significantly higher body weight than their lean counterparts (P<0.01; 








3.2 Apoptotic related gene expressions in obese and lean Zucker rats 
In this project, the effect of obesity as a metabolic disorder on gene expression levels 
of the pro- and anti-apoptotic members of the BCL-2 family of genes, good candidates 
for apoptotic index measurement, was investigated. Liver and colon were examined since 
obese individuals are more prone to colon cancer and liver disorder progression. 
Therefore, applying a paired t-test analysis the effect of obesity on apoptotic gene 
expression levels was assessed in obese versus lean individuals to find out the significant 
differences in obese compare to lean groups. 
3.2.1 The effect of obesity on pro- and anti-apoptotic gene 
expression levels in colon tissue 
In this part of the study, it was hypothesized that without any external insult, obesity 
does affect the pro- and anti-apoptotic gene expression levels in colon tissue. 
As shown in Fig.9, the anti-apoptotic Bcl-2 gene expression level is significantly 
lower in obese animals compare to their lean counterparts. The pro-apoptotic Bak, Bad 
and Bax genes are significantly up-regulated in obese animals. It seems that other genes 
followed the same expression level in both groups.  
 
3.2.2 The effect of obesity on pro- and anti-apoptotic gene 
expression levels in liver tissue 
In this part of the study, it was hypothesized that pro- and anti-apoptotic gene 
expression levels in liver tissue were affected by obesity genotype without external 
signals. Fig.10 shows that the apoptotic regulator gene P53 and its downstream genes, 
anti-apoptotic Bcl-XL, and pro-apoptotic Bax and Bak are significantly up-regulated in 
obese individuals. Pro-apoptotic Bad and Bik, and anti-apoptotic Bcl-2 gene expression 





Figure 9. Colonic pro- and anti-apoptotic gene expression profiles in non-injected Zucker rats 
Gene expression levels in distal colon mucosa in obese rats were assessed using 
quantitative Real-Time RT-PCR relative to their lean counterparts (base line) and 
normalized using B-actin housekeeping gene as an internal control. Bar graphs 
represent mean ±S.E.M of the relative fold change of individual pro- and anti 
apoptotic genes in obese colonic mucosa. Tissues were collected from 12 rats and 
expressions were measured in triplicate.  The asterisk (*) indicates a significant 
difference from the lean group (P<0.05). Blue bars represent gene expression in 













Figure 10. Hepatic Pro- and anti-apoptotic gene expression profiles of non-injected Zucker rats 
Gene expression in the liver of obese rats was assessed using quantitative Real-
Time RT-PCR and the final results were described relative to control lean animals 
(base line) and normalized using the 18srRNA housekeeping gene as an internal 
control. Bar graphs represent relative mean ±S.E.M of the fold change of individual 
pro- and anti apoptotic genes in obese hepatocytes. Tissues were collected from 12 
rats and expressions were measured in triplicate. The asterisk (*) indicates a 
significant difference from the lean group (P<0.05). Blue and red bars represent 










3.3  Differential apoptotic related gene expressions in Zucker rats after 
AOM administration 
        pro- and anti-apoptotic gene expression levels was measured in AOM injected 
obese and lean Zucker rats relative to the non-injected lean animals to follow the effect of 
obesity on apoptosis gene expression levels at three different time points- at three, nine, 
and twenty-four hours- post AOM injection. This part of current study was performed to 
more finely determine the possible changes in gene expression levels in obese animals 
compare to their lean counterparts after apoptotic signal induction. It was hoped that the 
results would elucidate the possible role of apoptosis on progression of colon cancer and 
liver dysfunction in obese individuals. All the results were statistically analyzed by paired 
t-test to find out the significant differences of gene expression levels between obese and 
lean individuals at each particular time point. 
 
3.3.1 BCL-2 family gene expression levels in colonic mucosa of 
Zucker rats after AOM injection 
 
All Zucker rats, except the control group, were injected with carcinogen AOM as an 
internal apoptotic signal inducer. Following this, eight animals in each group were 
terminated at three different sampling times in order to determine the effect of initial 
stages of DNA damage on anti- and pro-apoptotic gene expression levels of the BCL-2 
family as well as the possible synergistic effect of obesity on expression of these genes. 
 
As shown in Fig.11, at three hours after AOM injection, the apoptotic regulator gene 
P53 and its downstream pro-apoptotic gene expression levels are significantly different 
between obese and lean animals. P53, Bax, and Bad genes show higher expression levels 
in obese individuals, while Bik and Bak genes are expressed at lower levels than those 
seen in their lean counterparts. Although pro-apoptotic gene expressions are altered, anti-
apoptotic gene expression levels have not been changed at three hour post treatment in 
obese individuals compare to their lean counterparts. 
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Results in Fig.12 indicate that apoptotic regulator gene P53 and its downstream pro-
apoptotic Bad gene expression level is significantly lower in obese than in lean 
individuals at nine hours post AOM injection; however, pro-apoptotic Bax gene 
expression level is significantly higher in obese group at this time point. Two pro-
apoptotic Bik and Bak genes as well as the two anti-apoptotic genes, Bcl-2 and Bcl-XL, 
are expressed at the same level in both groups. 
Twenty-four hours after carcinogen administration, three pro-apoptotic genes- Bax, 
Bad and Bik - show significantly higher expression levels in obese individuals, while the 
other genes are expressed at similar level obese and lean animals (see Fig.13). 
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Figure 11. Colonic pro- and anti-apoptotic gene expression profiles in Zucker rats at three hours 
post AOM injection 
Three hours after carcinogen administration, the gene expression levels in distal 
colon mucosa in both lean and obese rats were assessed using quantitative Real-
Time RT-PCR relative to the control lean group (N=6) and normalized to the 
housekeeping gene B-actin as an internal control. Bar graphs represent mean 
±S.E.M of relative fold change of individual pro- and anti apoptotic genes in lean 
and obese colonic mucosa. Tissues were collected from 16 rats and expression was 
measured in triplicate. The asterisk (*) indicates a significant difference from the 
lean group (P<0.05).Blue bars represent gene expression in lean animals, while red 








Figure 12. Colonic pro- and anti-apoptotic gene expression profiles in Zucker rats at nine hours 
post AOM injection 
Nine hours after carcinogen administration, the gene expression levels in distal colon 
mucosa in both lean and obese rats were assessed using quantitative Real-Time RT-PCR 
relative to the control lean group (N=6) and normalized to the housekeeping gene B-actin 
as an internal control. Bar graphs represent the mean ±S.E.M of the relative fold change 
of individual pro- and anti apoptotic genes in obese and lean colonic mucosa. Tissues 
were collected from 16 rats and expression was measured in triplicate. The asterisk (*) 
indicates a significant difference from the lean group (P<0.05). Blue bars represent gene 











Figure 13. Colonic pro- and anti-apoptotic gene expression profiles in Zucker rats at 24 hours 
post injection 
Twenty-four hours after carcinogen administration, the gene expression levels in distal 
colon mucosa of lean and obese Zucker rats were assessed using quantitative Real-Time 
RT-PCR relative to the control lean group (N=6) and normalized to the housekeeping 
gene B-actin as an internal control. Bar graphs represent the mean ±S.E.M of the relative 
fold change of individual pro- and anti apoptotic genes in lean and obese colonic mucosa. 
Tissues were collected from 16 rats and expression was measured in triplicate.  The 
asterisk (*) indicates a significant difference from the lean group (P<0.05). Blue bars 












3.3.2  BCL-2 family gene expression levels in liver tissue of Zucker 
rats after AOM injection 
All obese and lean Zucker rats, except 12 rats, which constituted the control group, 
were injected with carcinogen AOM as an internal apoptotic signal inducer. Following 
this, eight animals in each group were terminated at three different sampling times. 
Following termination, very tiny part of the liver tissue was subjected to further study. 
Gene expression analysis was performed on extracted mRNA in order to determine the 
effect of initial stages of DNA damage on anti- and pro-apoptotic genes of the BCL-2 
family in this tissue.  The possible effect of obesity on expression of these genes and its 
possible effect on liver disease progression were investigated as well. It was hypothesized 
that AOM treatment would affect the expression level of indicated genes and this effect 
would differ between obese and lean individuals. 
As indicated in Fig.14, apoptotic regulatory gene P53 and its downstream gene pro-
apoptotic Bax is significantly up-regulated in obese animals at three hours after 
carcinogen administration. Other pro- and anti-apoptotic genes show the same expression 
level in both groups of animals. Based on the results on Fig.15, at nine hours post AOM 
injection, pro-apoptotic Bax expression level is higher in obese individuals compare to 
their lean counterparts. The other genes do not show significantly different expression 
levels in these two individual groups. Although it seems that Bad expression is lower in 
obese individuals, statistically this difference is not significant because the P value is 
0.056.  Fig.16 demonstrates the expression level of pro- and anti-apoptotic genes in obese 
and lean Zucker rats at twenty-four hours after AOM treatment. At this particular time, 
both pro- and anti-apoptotic genes, Bax, Bak, Bad and Bcl-2, show significantly higher 
expression levels in obese individuals, tumor suppressor gene P53 show lower expression 





Figure 14. Hepatic pro- and anti-apoptotic gene expression profiles in Zucker rats at three hours 
post AOM injection 
Three hours after carcinogen administration, the gene expression levels in liver tissue 
of Zucker rats (N= 16) were assessed using quantitative Real-Time RT-PCR relative to 
the non-injected lean animals (N=6) and normalized to the housekeeping gene 18srRNA  
as an internal control. Bar graphs represent the mean ±S.E.M of the relative fold change 
of individual pro- and anti apoptotic genes in lean and obese colonic mucosa. Tissues 
were collected from 16 rats and expression was measured in triplicate.  The asterisk (*) 
indicates a significant difference from the lean group (P<0.05). Blue bars represent gene 
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Figure 15.Hepatic pro- and anti-apoptotic gene expression profiles in Zucker rats at nine hours 
post AOM injection 
Nine hours after carcinogen administration, the gene expression levels in liver tissue 
of both obese and lean Zucker rats (N= 16) were assessed using quantitative Real-Time 
RT-PCR relative to the non-injected lean animals (N=6) and normalized to the 
housekeeping gene 18srRNA as an internal control. Bar graphs represent the mean 
±S.E.M of the relative fold change of individual pro- and anti apoptotic genes in lean and 
obese colonic mucosa. Tissues were collected from 16 rats and expression was measured 
in triplicate.  The asterisk (*) indicates a significant difference from the lean group 
(P<0.05). Blue bars represent gene expression in lean animals, while red bars represent 
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Figure 16. Hepatic pro- and anti-apoptotic gene expression profiles in Zucker rats at 24 hours 
post AOM injection 
Twenty-four hours after carcinogen administration, the gene expression levels in liver 
tissue of both obese and lean Zucker rats (N= 16) were assessed using quantitative Real-
Time RT-PCR relative to the non-injected lean animals (N=6) and normalized to the 
housekeeping gene 18srRNA as an internal control. Bar graphs represent the mean 
±S.E.M of the relative fold change of individual pro- and anti apoptotic genes in lean and 
obese colonic mucosa. Tissues were collected from 16 rats and expression was measured 
in triplicate.  The asterisk (*) indicates a significant difference from the lean group 
(P<0.05). Blue bars represent gene expression in lean animals, while red bars represent 











3.4 Colonic BCL-2 gene expression patterns in Zucker rats after AOM 
injection 
In this part of the study, it was hypothesized that obesity would affects the BCL-2 
family of gene expression patterns in colon tissue and obese individuals show different 
apoptotic involving gene expression patterns within 24 hours post AOM injection from 
their lean counterparts. In order to accomplish this, the overall effect and overall 
differences of the gene expression patterns in these individual groups were examined 
statistically. 
As it is shown in Fig.17-A, obese and lean animals do not show the same Bcl-2 gene 
expression pattern in colon tissue. The one way ANOVA test shows that overall, within 
24 hours after AOM injection, obese animals show significantly different Bcl-2 gene 
expression pattern compare to their lean counterparts (P= 0.034). This achievement gives 
support to the results of the Tukey HSD test.  This complementary test revealed that there 
are significant differences at three and twenty four hours post AOM injection (P=0.02) 
compare to non-injected animals at time zero. As seen in Fig.17-B, obese and lean Zucker 
rats show a significantly different Bcl-XL gene expression pattern in colon tissue within 
twenty-four hours after AOM injection (P=0.024). The Tukey HSD test revealed that 
there are significant differences at three and twenty-four hours after carcinogen injection 
and in both groups anti-apoptotic Bcl-XL gene expression at three hours post treatment is 
significantly higher than what it is at 24 hours (P=0.04). 
As seen in Fig.17-C, one way ANOVA test showed that Bax overall gene expression 
pattern is significantly different in obese and lean Zucker rats within 24 hours after AOM 
injection (P=0.01).  In obese individuals, Bax gene expression is significantly up-
regulated after AOM administration and reaches its peak at three hours post injection, and 
the results of following Tukey post hoc test revealed that at this time point its expression 
level is significantly higher than what it is at time 0 and 24. In lean animals, Bax 
expression reaches its peak at nine hours after treatment that is significantly higher than 
time 0 and 24. In both groups, Bax expression is significantly down-regulated after nine 
hours post injection, and at twenty-four hours after AOM administration its expression 
level is significantly lower than what it is at nine hours (P=0.00).  
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The overall one way ANOVA  revealed that Bad gene expression pattern, within 
twenty-four hours after AOM injection, in obese animals is significantly different from 
their lean counterparts (P=0.002) with a peak at three hours post injection, while its gene 
expression level reaches the peak in lean animals at nine hours post injection. However, 
the Tukey HSD test does not show any significant difference (Fig.17-D). Moreover, Bik 
gene expression pattern is significantly different in obese animals from their lean 
counterparts and shows significantly lower level in obese individuals (P=0.000) (Fig17-
E). Statistical testing indicated that in obese individuals, the Bik gene is down-regulated 
over 24 hours after AOM injection, but in lean animals is up-regulated over the time. 
However, in both groups, its expression level at twenty-four hours post injection is 
significantly different from time 0 (P=0.006). Within the same time intervals, obese and 
lean Zucker rats showed an opposite Bak expression pattern and based on the overall 
ANOVA results, with significantly lower expression in obese animals (P=0.001). In lean 
individuals, Bak is up-regulated after AOM administration with the highest level at three 
hours post injection, while in obese rats it is down-regulated with the lowest expression 
level at particular time point (Fig.16-F). However, the Tukey HSD test revealed that there 
are no significant differences among time points 0, 3, 9, and 24 hours post injection. 
It seems that dynamically anti-apoptotic genes follow the same expression patterns in 
obese individuals but different patterns in their lean counterparts (Fig.17-A and B). 
Furthermore, the pro-apoptotic gene expression patterns are different from one gene to 
another and each particular gene shows dynamically specific pattern in obese and lean 
individuals (Fig.17-C, D, E and F). However, Bad gene expression pattern in obese 
animals is very similar to anti-apoptotic genes (Fig.17-D and A,B). 
Fig.18 shows the P53 gene expression pattern following AOM administration. As the 
ANOVA results indicated, there is an overall significant difference between P53 gene 
expression patterns in obese and lean individuals within 24 hours post AOM injection 
(P=0.001). In obese individuals, P53 expression peak is at three hours post injection 
while in their lean counterparts is at nine hour. Further analysis applying the Tukey post 
hoc tests revealed that in either obese or lean individuals, at three hours after injection 
P53 expression is significantly higher than what it is at time zero and twenty four hours 
(P=0.008).  
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Figure 17.  Anti- and pro-apoptotic gene expression patterns in colon epithelium of Zucker rats after 
AOM injection 
Obese and Lean Zucker rats were injected with carcinogen AOM and terminated at three 
different time intervals. Time 0 indicates the control group that were not injected. The anti-
apoptotic and pro-apoptotic gene expressions were assessed using quantitative Real-Time RT-
PCR relative to the non-injected animals in each individual group and normalized to the 
housekeeping gene B-actin as an internal control. The anti-apoptotic Bcl-2 and Bcl-XL results 
were presented in panel A and B, respectively, and pro-apoptotic Bax, Bad, Bik, and Bak gene 
expression patterns were presented in sections C, D, E, and F, respectively. Line graphs represent 
the mean ±S.E.M of the relative fold change of individual genes at four different time points in 
obese and lean colonic mucosa. Tissues were collected from 60 rats, 30 obese and 30 lean, and 
each individual gene expression was measured in triplicate. The asterisk (*) indicates a 
significant difference over the time (P<0.05). Blue graphs represent gene expression pattern in 
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Figure 18. P53 gene expression pattern in colon epithelium of Zucker rats after AOM injection 
Obese and Lean Zucker rats were injected with AOM and terminated at three different time 
intervals. Time 0 indicates the control group that were not injected. The apoptotic regulatory P53 
gene expression was assessed using quantitative Real-Time RT-PCR relative to the non-injected 
animals in each individual group (N=12) and normalized to the housekeeping gene B-actin as an 
internal control. Line graphs represent the mean ±S.E.M of the relative fold change of individual 
genes at four different time points in obese and lean colonic mucosa. Tissues were collected from 
60 rats, 30 obese and 30 lean, and each individual gene expression was measured in triplicate. 
The asterisk (*) indicates a significant difference over the time (P<0.05). Blue graphs represent 
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3.5 Hepatic BCL-2 family gene expression patterns in Zucker rats after 
AOM injection 
In this part of the study, it was hypothesized that obesity would affect the BCL-2 family of 
gene expression patterns in obese individuals such that they show different apoptotic gene 
expression patterns than their lean counterparts within 24 hours of AOM injection. One way 
ANOVA statistical tests were performed to examine the overall differences in gene expression 
patterns between obese and lean animals followed by a Tukey HSD post hoc test to show the 
overall significant differences between four individual time points in both groups. 
As described in Fig.19-A, obese and lean animals show roughly the same Bcl-2 gene 
expression pattern in liver. However, the one way ANOVA shows significant difference between 
the two groups (P= 0.014). This supports the results of the Tukey HSD test, which revealed that 
there are significant differences in expression between three, nine and twenty four hours post 
AOM injection time points in both groups. In other words, at three hours after treatment, the Bcl-
2 gene expression is significantly higher than what it is at nine (P=0.034) and twenty-four hours 
(P=0.000). As seen in Fig.19-B, obese and lean Zucker rats show a similar profile of Bcl-XL 
expression pattern, but this pattern statistically is different in liver over twenty-four hours after 
AOM injection (P=0.00). The Tukey HSD test revealed that Bcl-XL gene expression at three 
hours post injection is significantly higher than what it is at zero and twenty four hours (P=0.012 
and P=0.003 respectively) and at nine hours compare to what it is at zero and twenty four hours 
in both lean and obese animals (P=0.019 and P=0.005 respectively). 
As seen in Fig.19-C, a one way ANOVA test showed that the overall Bax expression pattern 
in liver is significantly different between obese and lean Zucker rats within 24 hours after AOM 
injection, but its expression pattern profile seems very similar.  In obese and lean individuals, 
Bax gene expression is significantly up-regulated after AOM administration, and a Tukey post 
hoc test revealed that in both obese and lean rats the Bax gene expression at time zero is 
significantly lower than what it is at three, nine, and twenty four hours after injection.  
A one way ANOVA  revealed that Bad gene expression pattern, within twenty-four hours 
after AOM injection, in obese animals is significantly different from their lean counterparts 
(P=0.02) with a peak at nine hours post injection in obese group. Also it seems that the Bad gene 
expression profile is diferent in obese and lean individuals. The Tukey HSD test does not show 
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any significant difference between different individual time points (Fig.19-D). Moreover, Bik 
gene expression pattern, either by profile or statistically, does not show any difference in lean 
and obese animals as well as no significant change between different time intervals (Fig.19-E). 
Bak expression pattern, based on the overall ANOVA results, is significantly different in obese 
animals from their lean counterparts over 24 hours after AOM administration (P=0.02). In both 
obese and lean individuals Bak is up-regulated after AOM administration with the highest level 
at three hours post injection which is significantly higher than time zero (P=0.002)( Fig.19-F). 
It seems that Bad is the only gene that’s expression pattern profile is different in obese and 
lean individuals (Fig.19-D), and all the other genes, dynamically, follow the same expression 
profile in both groups. Interestingly, these profiles are different from one gene to another. 
Fig.20 shows the P53 gene expression pattern in liver. The ANOVA results indicated that, 
there is a significant difference between the overall P53 gene expression pattern in obese and 
lean individuals within 24 hours post AOM injection (P=0.002). The dynamic pattern seems 
different between the individual time points as well. Also, in lean animals, P53 is up-regulated 
after injection and reaches its expression peak at nine hours post injection and is then down-
regulated by twenty four hours post injection. Further analysis applying the Tukey post hoc tests 
revealed that at nine hours post injection P53 gene expression in both groups is significantly 
different from what it is at twenty four hours after injection (P=0.002).  
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Figure 19. Anti- and pro-apoptotic gene expression pattern in liver tissue of Zucker rats after AOM 
injection 
Obese and Lean Zucker rats were injected with carcinogen AOM and terminated at three 
different time intervals. Time 0 indicates the control group that were not injected. The anti-
apoptotic and pro-apoptotic gene expressions were assessed using quantitative Real-Time RT-
PCR relative to the non-injected animals in each individual group and normalized to the 
housekeeping gene 18srRNA as an internal control. The anti-apoptotic Bcl-2 and Bcl-XL results 
were presented in panel A and B, respectively, and pro-apoptotic Bax, Bad, Bik, and Bak gene 
expression patterns were presented in sections C, D, E, and F, respectively. Line graphs represent 
the mean ±S.E.M of the relative fold change of individual genes at four different time points in 
obese and lean colonic mucosa. Tissues were collected from 60 rats, 30 obese and 30 lean, and 
each individual gene expression was measured in triplicate. The asterisk (*) indicates a 
significant difference over the time (P<0.05). Blue graphs represent gene expression pattern in 






Figure 20. P53 gene expression pattern in liver tissue of Zucker rats after AOM injection 
Obese and Lean Zucker rats were injected with AOM and terminated at three different time 
intervals. Time 0 indicates the control group that were not injected. The apoptotic regulatory P53 
gene expression was assessed using quantitative Real-Time RT-PCR relative to the non-injected 
animals in each individual group (N=12) and normalized to the housekeeping gene 18srRNA  as 
an internal control. Line graphs represent the mean ±S.E.M of the relative fold change of 
individual genes at four different time points in obese and lean colonic mucosa. Tissues were 
collected from 60 rats, 30 obese and 30 lean, and each individual gene expression was measured 
in triplicate. The asterisk (*) indicates a significant difference over the time (P<0.05). Blue 
graphs represent gene expression pattern in lean animals, while red graphs represent gene 









Chapter 4 Discussion 
 
In the first part of this study, some of pro-and anti apoptotic members of the BCL-2 
family of genes were examined to determine if their expression level is altered in obese 
individuals, and if any of the differences found can explain why obese animals are more 
sensitive to the progression of colon cancer and liver diseases. 
The second part of this study focused on the alteration of apoptotic related gene 
expression in the colonic epithelium and liver tissue of obese and lean rats within 24 
hours of AOM- induced DNA damage. 
Although, different studies have investigated the role of apoptosis and its alteration in 
colon cancer and hepatic steotasis in recent years, knowledge in this field is still limited. 
In particular, there is a gap in the current understanding of apoptotic gene expression 
levels in obese individuals. Expression of these genes may play a role in the increased 
incidence of variety of diseases including colon cancer and hepatic steotasis. 
Apoptosis is a highly regulated process which is basically defined by morphological 
changes including chromatin condensation, nuclear fragmentation and formation of 
apoptotic bodies. Apoptosis could be affected by tumor suppressor gene P53. In normal 
cells and in normal environment, P53 protein is rapidly degraded and stayed at very low 
levels within the cell. However, some of the stress signals, such as DNA damage, 
hypoxia, oncogene activation, and metabolic changes induce the rapid elevation of P53 
mRNA and/or protein levels (84). As mentioned before, one of the most important 
functions of P53 as a tumor suppressor gene is its ability to inhibit cell growth by 
inducing either cell cycle arrest or apoptosis. Furthermore, the function of P53 protein as 
a transcription factor contributes to both responses  . Many cellular genes have been 
shown to be transcriptionally regulated by P53. These genes can be broadly divided into 
those involved in cell cycle arrest and those that contribute in the apoptotic response. It 
should be noticed that these two groups are separable (4). In fact, the choice of response 
to P53 is strongly influenced by the cell type, the cellular environment, and the type of 
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signal. As an example, it was proposed that repairable low level DNA damage, which 
induces low levels of P53, leads to cell cycle arrest, while extensive and un-repairable 
DNA damage induces high levels of P53 and leads to apoptosis (85). P53-induced 
apoptosis has been shown to regulate both Bcl-2 and Bax expressions in vivo (86). 
Expression of the BCL-2 family of genes regulates cell survival by controlling apoptosis. 
Bcl-2 and Bcl-XL genes and their encoded proteins are anti-apoptotic members, whereas 
others, such as Bax, Bad, Bak and Bik genes and their protein products are pro-apoptotic. 
The BCL-2 family of proteins are able to form homo- and/or hetero-dimers among 
themselves; their association and the relative ratio of pro- to anti-apoptotic genes and 
proteins are thought to be responsible for directing the cells toward death or survival. 
Current data have not clarified which dimers are critical regulators of apoptosis. 
In addition, it is worthy of mention that oxidative stresses have a significant role in the 
development of many human diseases, such as cancer and liver dysfunctions (87), and 
different studies have shown the effective role of either natural or synthetic antioxidants 
as pharmaceutical agents to prevent and cure of these diseases (88). Oxidative stresses, in 
aerobic life, arise from both endogenous and exogenous sources such as higher level of 
glucose metabolism that in turn generate hydroxyl radicals and other reactive oxygen 
species (ROS), which as well as hyperglycemia trigger programmed cell death (89).  
Zucker obese rats show hyperglycemia and subsequently more reactive oxygen 
species; therefore, it was expected that in these animals P53 and its transcriptionally 
regulated apoptotic involving genes would show higher expression levels. It was 
hypothesized that obesity as a metabolic disorder and its consequent problems such as 
hyperinsulenemia, hyperglycemia, and higher level of ROS should up-regulate P53 and 
make tissue more sensitive to apoptosis and disease progression either before or after 
AOM injection and DNA damage induction. Moreover, since obesity does affect the P53 
expression level, it could change the pro- and anti-apoptotic gene expression pattern of 
BCL-2 family.   
4.1 Effects of obesity on apoptosis in colon tissue 
Colon is a highly proliferative tissue with a constant turnover of cells. This organ is 
sensitive to tumor development, and it was documented that colorectal cancer is the third 
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most common cancer in both men and women including  9% of all cancer deaths in 2008 
(Cancer Facts and Figures, Annual report of American Society of Cancer). 
Epidemiological data suggests that obesity is a risk factor for colon cancer . The animal 
model of human obesity, Zucker obese rats which were used in this study, has been 
proven to be more sensitive to carcinogen-induced colon cancer than their lean 
counterparts (90, 91). This study was carried out to examine if the obese genotype of the 
Zucker rat animal model alters the apoptotic gene expression prior to any disease 
development with and without carcinogen injection. 
4.1.1 The effect of obesity on pro- and anti-apoptotic gene 
expression levels in colon tissue prior to AOM injection 
A differential apoptotic gene expression study was performed on obese and lean 
Zucker rats by means of quantitative Real-Time RT-PCR to figure out the probable effect 
of obesity on apoptotic gene expression. The data in Fig.9 shows that expression of the 
pro-apoptotic Bax, Bad and Bak genes is significantly up-regulated in obese animals, 
while, anti-apoptotic Bcl-2 gene expression is significantly down-regulated in obese 
individuals. The ratio of Bcl-2/Bax genes and/or proteins is one the most important 
indicators of whether a cell will survive or undergo apoptosis (6, 97), and it was shown 
that if this ratio is lower than one, then that particular cell undergoes apoptosis. In current 
study, this ratio in obese colon mucosa is about 0.1 which is lower than what it is in lean 
mocusa (1.25) and suggests that in the colon of obese individuals cells are more sensitive 
to apoptosis. This result confirms the previous results seen in adipose tissue of obese 
Zucker rats (92).  The P53 gene, which can work as either a cell survival factor or 
apoptotic activator did not show a significant change in expression level in both groups in 
colon mucosa. It has been previously reported that  Bcl-XL gene expression is up-
regulated by insulin-like growth factor-1/IGF-1 (6), which is higher in obese individuals 
(93). However, in this part of current study, Bcl-XL gene expression level was not 
changed significantly in obese animals. The anti-apoptotic Bik gene presents a 
widespread tissue distribution, and may be rapidly turned over during apoptosis (47). 
Also, its regulation takes place at the transcriptional level with over-expression of P53 
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(94). Current results can not confirm or decline the previous one since either P53 or Bik 
gene expression levels has not changed in non-injected obese and lean animals (Fig.9). 
Pro-apoptotic Bax protein induces apoptosis by permeating the mitochondrial 
membrane, allowing Cytochrome C release, initiating apoptosis through caspase 
activation and apoptosome complex formation. It was previously shown in our research 
group that elements of the sphingolipid pathway are altered in obese individuals without 
carcinogen injection and prior to cancer development. Also, applying Western blot and 
densitometric analysis, it was indicated that Bax protein is 100% up-regulated in obese 
colon tissue compared to lean. Furthermore, it was demonstrated that Bcl-2 protein is 
significantly down-regulated in obese Zucker rats (Burrows and Bird, unpublished data). 
On the other hand, some of these candidate genes could show different reaction at 
protein level due to either post transcriptional or post translational changes that may arise. 
For instance, P53 is one of the most important proteins for determining cell fate. In fact, 
although it was expected that P53 gene would show a higher expression level in obese 
individuals, current data indicate no change in its gene expression level. However, it is 
still possible that the protein expression level could be up-regulated in obese animals. 
Also, at the pro- and anti-apoptotic protein level, cell fate depends on the homo- and/or 
hetero-dimmers which would be oligomerized inside a cell. 
As a conclusion, based on these results, the higher expression levels of Bax gene and 
protein and lower expression levels of Bcl-2 gene and protein along with up-regulation of 
other pro-apoptotic genes in obese colon mucosa as well as the lower ratio of Bcl-2/Bax 
genes suggest that obese individuals are more sensitive to apoptosis and are more prone 
to colonic disease progression.  
4.1.2 Early alteration of apoptotic gene expression levels in Zucker 
rat’s colonic mucosa after AOM injection 
Alteration of expression level of some apoptosis genes in colonic mucosa of Zucker 
obese and lean rats was estimated after exposure to azoxymethane (AOM) by means of 
quantitative Real-Time RT-PCR to find out the probable effect of obesity on the 
expression of these genes. The mechanism of cancer initiation by the carcinogen 
azoxymethane have been described (95). Activated metabolites of this agent form O6-
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methylguanine in DNA, which induce the GC to AT transitions in vitro and in vivo (96) , 
that are associated with tumor initiation (97). Some of the damaged cells are repaired by 
internal repair systems, but some are not able to be repaired and will be eliminated by 
apoptosis; therefore, only a few numbers of surviving damaged cells have the opportunity 
to change to pre-cancerous cells. It was described that “ in the early stage of experimental 
tumorogenesis, mitosis and nucleic acid synthesis is inhibited because of carcinogen-
induced apoptosis and these alterations may induce cell cycle arrest and apoptosis after 
DNA damage” (98). However in late stages of DNA damage induction and carcinogen 
injection, mitosis is activated and depends on the ratio of cell division to apoptosis some 
cells change to pre-cancerous ones and then unbalanced cell proliferation and death 
causes tumorogenesis.  Moreover, there are accumulating data suggest that apoptotic 
genes and proteins , such as those of the BCL-2 family, are associated with the 
pathogenesis of some types of malignancies (99). Therefore, amongst other cell death 
evaluating methods, studies on apoptotic gene expression seem valuable. In addition, it 
was previously reported that more epithelial cells are eliminated through apoptosis in 
distal part of the colon (left side of the body, 0-4 cm from the rectal end) than proximal 
(right side of the body, 8-16 cm from the rectal end) after carcinogen exposure. Also, 
AOM treatment causes profound damage to the distal colon in male Fisher rats, and only 
one AOM treatment provides more tumors in distal colon (100). This finding was 
confirmed in 2001 by Hong and his research group (63). Furthermore, in 1995 Bird et. al. 
explained that during experimental colon carcinogenesis, pre-cancerous cells appeared 
earlier and more rapidly in distal versus proximal colon and the amount of fat 
consumption did affect the tumorogenesis (101). It was also reported that majority of 
tumors in obese Zucker rats are located in distal region of colon tissue and obesity does 
directly affect the number of tumors, and in fact, “association between obesity and colon 
cancer is more often noticed in the distal rather than proximal colon” (Saxena and Bird, 
un-published data). Consequently, it seems that more molecular changes such as 
apoptosis and cell proliferation occur in distal colon after carcinogen exposure; therefore, 
in the current study, the distal colon has been studied. Based on the current results, three 
hours post AOM injection, P53 and its downstream pro-apoptotic gene’s expression 
levels significantly changed in obese animals. P53, Bax, and Bad genes show higher 
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expression, while Bik and Bak genes show lower expression level in obese individuals 
compare to their lean counterparts. As it was mentioned earlier, P53 gene is responsible 
for different functions at the molecular level in cells, which can be classified by the type 
and amount of cellular stresses. Since a high level of DNA damage is usually induced by 
AOM injection, if the tumor suppressing function of P53 is considered, higher expression 
levels of P53 may result in less cell proliferation and more cell cycle arrest or more 
apoptosis. In addition, higher expression level of P53 could explain up-regulation of its 
down-stream targets such as Bax and Bad in obese individuals. On the other hand, anti-
apoptotic gene expression levels have not been changed at this time point in obese 
individuals compared to their lean counterparts, and the Bcl-2/Bax ratio in obese colon 
mucosa is 0.25, thus three hours after DNA damage induction obese individuals are more 
prone to apoptosis. 
These results as expected agree with the observations of Hirose et. al. They found 
increasingly damaged cells with typical morphologic characters of apoptotic cells in 
distal part of colonic epithelium four hours after AOM treatment (64). Also, the same 
research group recorded that at eight hours after carcinogen treatment, the number of 
damaged cells as well as apoptotic bodies was increased and a significant decrease in the 
number of mitotic cells was observed. However, in the current study, it was noticed that 
at nine hours after DNA damage initiation, the apoptotic regulator gene P53 and its 
downstream target pro-apoptotic Bad gene expression levels are significantly lower in 
obese individuals, while the pro-apoptotic Bax gene expression level is significantly 
higher at this time point in the obese group compared to their lean counterparts, and Bak, 
Bik and two anti-apoptotic genes follow the same expression level in both groups. 
Although this part of results regarding P53 expression level is not as expected (see 
Fig.12) the ratio of Bcl-2/Bax is still lower in obese colon and is equal to 0.05, which 
suggests that at nine hours post injection the colonic epithelial cells of obese individuals 
are more sensitive to cell death.  
Hirose et. al. also explained that three days after AOM injection, the number of 
apoptotic cells were decreased (64); however, current study cannot confirm or decline the 
above data since one day after injection was the last time interval investigated. Refer to 
Fig.13 at 24 hours post AOM administration, pro-apoptotic genes, Bax, Bad and Bik, 
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show significantly higher expression levels in obese individuals and other genes follow 
the same expression level in both groups. Also, the Bcl-2/Bax ratio is 0.1 in obese 
animals which is lower than what it is in their lean counterparts. Therefore, it can be 
concluded that one day after DNA damage induction, obese individuals could be more 
sensitive to apoptosis and disease progression because of unbalanced cell 
death/proliferation. Previously, Hong and his collaborators using a “rat diet/colon 
tumorogenesis model system” figured out that they can follow tumor development in this 
system by looking at the early stages (0-12 hours) of tumorogenesis after carcinogen 
administration (63). Applying the TUNEL assay and a morphological study, this research 
group found that from time zero to nine hours post AOM injection, the apoptotic index 
initially increases in the colon epithelial cells and then decreases again up to 12 hours 
post injection. Also, they reported that in rats that were fed with high fat diet the 
apoptotic index increased up to nine hours and then declines, but in rats were fed with 
low fat diet the reaction of colon cells to AOM injection is different and apoptotic index 
simply increases over the time. Therefore, the apoptotic reaction of low fat diet animals 
within the first 12 hours after carcinogen administration was different from the high fat 
diet animals. Bax is the most important pro-apoptotic member of BCL-2 family that 
research on its expression level has been the focus of most of the apoptosis related 
studies. This gene and its protein product have the ability to inactivate the anti-apoptotic 
members and/or increase the activity of other pro-apoptotic members. In current study, 
Bax gene expression level is higher in obese animal with or without apoptotic signal that 
explain that why obese individuals could be more prone to apoptosis.   
Regarding these results, the effect of obesity on overall pro- and anti-apoptotic gene 
expression patterns during the first twenty-four hours after carcinogen injection were 
examined statistically. In this part of results, obese and lean injected animals were 
compared to the non-AOM injected ones in their own group. In this way, the effect of 
carcinogen administration regardless of metabolic condition of animals was followed at 
three different time points. Then these effects were compared between the obese and lean 
groups to find out whether or not apoptotic gene expression patterns in obese individuals 
are statistically different from their lean counterparts. It was very interesting to find that 
the anti-apoptotic Bcl-2 and Bcl-XL genes follow a similar expression pattern in obese 
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groups and are different from what it is noticed in lean individuals.  Moreover, pro-
apoptotic gene expression patterns in obese and lean animals are statistically different 
from each other. These results could explain that why obese colon is more susceptible to 
disease progression compare to its lean counterpart. As seen in figure 17, anti-apoptotic 
genes in obese animals show the maximum expression at three hours post AOM injection 
which is significantly higher than what it is at twenty four hours and suggest that one day 
after DNA damage induction, obese group show more trends to apoptosis. 
All together, as it was hypothesized, within 24 hours of initial stages of AOM –
induced colon tumorogenesis, obese individuals are more sensitive to DNA damage. 
Also, regarding the apoptotic gene expressions the reaction of obese and lean Zucker rats 
to carcinogen injection is statistically different, which confirms the previous results in a 
“rat diet/colon tumorogenesis model system” (63). However, still more investigation in 
this project, such as TUNEL assay, apoptotic protein expression analysis,  and 
morphological studies at three or even more time intervals, is required to find out the 
effect of obesity on apoptotic index in colonic tissue after carcinogen administration.  
4.2 Obesity effects apoptosis in liver tissue 
Hepatocellular apoptosis is a key outcome of many forms of liver disorders and is 
triggered by signals that activate either the extrinsic apoptotic pathway through the 
induction of death receptor expression, or the intrinsic apoptotic pathway through up-
and/or down-regulation of the BCL-2 family of genes. The consequences of programmed 
cell death are more noticeable as more hepatocytes are eliminated leading to liver 
dysfunction.  In recent years, more understanding about apoptotic signalling processes 
and the genes and proteins involved has been achieved, so more efficient therapeutic 
control mechanisms might be available in the future to help combat this problem. 
In liver tissue, dysregulation of programmed hepatocyte death such as failure to 
undergo apoptosis can cause severe problems ranging from autoimmune diseases to 
cancer, or a high incidence of apoptosis which contributes to the progression of 
pathological states including chronic liver diseases (66). Indeed, cells are divided in two 
types depending on the involvement of mitochondria in apoptosis (35). Hepatocytes are 
classified as the type II cells which mean that mitochondria play an essential role in the 
 76
regulation of apoptosis and are actually considered strategic centers in the control of cell 
death. Given that mitochondria plays critical role in hepatocellular apoptosis, the P53 
gene and some of its downstream genes such as BCL-2 gene family members are good 
candidates to be investigated.   
Previously, it was reported that obese mice show hepatic steatosis (102). About 10 
years later, it was documented that obese patients are more susceptible to acute liver 
failure when they are exposed to apoptotic signals(103). Moreover, in vitro studies using 
liver cancer cell lines have shown that free fatty acids promote up-regulation of the 
Fas/CD95 receptor and consequently activate the extrinsic apoptotic pathway (77). Also, 
it was reported recently that Sprague-Dawley rats were fed in high fat diet show more 
TNF-α, caspase3, and Bax mRNA expressions and no change in anti-apoptotic Bcl-2 and 
Bcl-XL expressions compared to the control group (104). In current study, after tissue 
harvesting it was noticed that in Zucker rats the obese livers were significantly larger than 
the lean ones and appeared pale and creamy with lighter colour compared to the darker 
red colour of their lean counterparts. Furthermore, it was previously shown in our 
research group that obese animals have hepatic steotasis characterized by lipid 
accumulation within the hepatocytes, which confirms the results in other animal models, 
while the lean liver shows normal histology (105). 
 
 
Figure 21. Histology of obese and lean liver in Zucker rats 
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Representative liver histology, magnification _100: a segment of liver was fixed in a buffered formalin 
solution and was stained with haematoxylin (staining the nuclei black) and eosin (staining the cytoplasm 
pink). (a) liver tissue from Zucker obese rat, yellow arrows show variable sizes of lipid droplets in 
hepatocytes; (b) liver tissue of Zucker lean rat shows normal liver architecture.  
Adapted by permission from Macmillan Publishers Ltd: [International Journal of Obesity] (105), copyright 
(2006)  
 
The expression level of the most important pro- and anti-apoptotic genes of the 
intrinsic apoptotic pathway were assessed in order to determine if the expression of these 
genes was altered in the liver of obese individuals before and after AOM administration. 
As some of these genes are regulated transcriptionally by the tumor suppressor P53, it 
was valuable to see if any alterations occurred at the gene expression level. 
Results of current study show that before DNA damage induction through carcinogen 
injection, apoptotic regulator gene P53 and its downstream targets, anti-apoptotic Bcl-XL 
as well as pro-apoptotic Bax and Bak are significantly up-regulated in the liver of obese 
individuals. Pro-apoptotic Bad and Bik show similar expression level in obese and lean 
animals. Perhaps, if the transcriptional regulatory activity of P53 is considered in this 
case, a higher expression level of P53 could be correlated with different incidence of 
apoptosis and/or hepatic tumor formation in obese animals. As it was mentioned earlier, 
Bcl-XL expression is up-regulated by higher level of insulin-like growth factor-1 (IGF-1) 
(6, 93) in obese animals. Anti-apoptotic Bcl-2 gene expression level in obese animals is 
not different from their lean counterparts and confirms the previous results in Sprague-
Dawley rats fed with high fat diet (104). 
As mentioned earlier, obesity correlates with higher oxidative stress due to 
hyperglycaemia. Furthermore, liver steatosis is closely associated with liver cell death. 
Increased expression of death receptors in obese livers sensitizes these cells to pro-
apoptotic signals, consequently triggering excessive hepatocyte apoptosis and 
inflammation (77). Also, in our research group applying Western blot and densitometric 
analysis in two different projects, it was shown that Bax protein is up-regulated by 
approximately 100%, and Bcl-2 protein expression level is approximately 75% lower in 
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obese Zucker rats compare to their lean counterparts (Naahidi and Bird, Burrows and 
Bird, unpublished data).   
Due to prolonged oxidative stresses and steatosis, it was hypothesized that obese 
individuals are more sensitive to apoptosis. Current results approve this hypothesis and 
are in accord with previous studies; since, over expression of pro-apoptotic genes along 
with a higher expression level of P53 and a lower Bcl-2/Bax ratio in obese individuals, 
which is 0.4 compare to 1.2 in their lean counterparts, suggest that obese liver tissue is 
more prone to programmed cell death and disease progression. 
In the next part of this study Zucker obese and lean rats were exposed to AOM 
carcinogen to induce DNA damage and apoptosis to investigate the hypothesized 
alteration of some apoptotic gene expression levels in liver tissue applying quantitative 
Ral-Time RT-PCR. At three hours post injection, as expected, the tumor suppressor gene 
P53 and its downstream transcriptional target genes Bax are significantly up-regulated in 
obese individuals. Anti-apoptotic and other pro-apoptoticgenes show the same expression 
levels in both groups of animals. A higher expression level of P53 along with a lower 
Bcl-2/Bax ratio in obese individuals (0.3 in obese compare to 1.3 in lean animals) may 
indicate more sensitivity of obese animals to DNA damage in the first three hours of 
apoptosis induction. However, at 9 hours after injection, Bax is the only gene that its 
expression level is changed in obese individuals. Bax is up-regulated in obese animals 
while the other genes unchanged. The Bcl-2/Bax ratio is 0.12 in obese individuals, which 
suggests at nine hours post injection obese individual’s liver cells are still more prone to 
apoptosis. Pro-apoptotic Bax, Bad, Bak and anti-apoptotic Bcl-2 gene expression levels 
are significantly higher in obese animals at 24 hours after DNA damage. The only part of 
current results that confirm the previous data about the effect of higher IGF level of obese 
animals on Bcl-XL higher expression level is achieved in non-injected animals and results 
after AOM injection decline that. In fact, it seems that  after carcinogen injection, the 
effect AOM-induced apoptotic signals are more important and more effective than higher 
IGF level in obese individuals because after apoptotic signal induction, the anti-apoptotic 
Bcl-XL gene expression level did not changed in obese animals compared to their lean 
counterparts.  
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The effect of obesity on overall pro- and anti-apoptotic gene expression patterns 
during the first twenty-four hours after carcinogen injection was statistically examined as 
well. Obese and lean injected animal were compared to the non-injected ones within their 
own group in order to follow the effect of AOM administration and DNA damage 
induction without considering the effect of obesity as a metabolic disorder. The results 
indicate that the Bcl-2, Bcl-XL, Bax, and Bik gene expression profiles are roughly similar 
in both groups; however the overall anti-apoptotic Bcl-2 and Bcl-XL as well as pro-
apoptotic Bax gene expression patterns are different in obese animals from their lean 
counter parts over the first twenty-four hours after AOM injection. Also, P53, Bad, and 
Bik gene expression patterns were significantly changed in obese individuals. As 
expected, after carcinogen injection, obese individuals show a different reaction to DNA 
damage from their lean counterparts. Consistently, the altered levels of pro- and anti-
apoptotic gene expressions in liver tissue at three different time intervals post AOM 
injection, as well as lower Bcl-2/Bax ratio in obese individuals suggest an increase in pro-
apoptotic signals in obese liver tissue, which in turn would explain the reason that why 
these animals are more susceptible to liver disease progression such as liver steatosis. 
Current results along with previous results in our research group not only support our 
hypothesis, also confirm previous studies reporting that steatotic livers are primed for 
apoptosis (103). As there are many other genes and proteins involved in mediating 
apoptosis, further investigation, such as assessing the pro- and anti-apoptotic protein 
expression level and morphological studies, is required to investigate the exact apoptotic 
index and the role of these genes and proteins in triggering apoptosis in steatotic liver. 
4.3 Apoptotic gene expression differences between liver and colon  
 
Liver and colon tissues possess completely different histology and functions. 
Previously it was shown that AOM injection cause DNA damage in colon and liver, 
which is known to induce tumors in these tissues, and it was hypothesised that the 
formation and persistence of methylated  DNA during replication may be responsible for 
the initiation of tumors (106). On the other hand, it was noticed that after AOM injection, 
in rat model, the initial DNA damage is higher in liver compared to colon, although liver 
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tumors have not been reported to be produced by a single dose of the carcinogen. (63). 
Also, after carcinogen administration, DNA damage persists in rat colon, but not in rat 
liver, which indicates the grater ability of liver to remove damaged DNA either through 
apoptosis or repair the damaged DNA (106). Consistent with these results, in the last part 
of this study, it was hypothesized that the reaction of obese and lean Zucker rats to AOM 
induced apoptotic gene expression is different in liver and colon tissues. 
As seen in Fig.17-C and 19-C, applying two way ANOVA statistical method, the 
overall  pro-apoptotic Bax gene expression pattern in liver is not significantly different 
from colon tissues of obese and lean Zucker rats over 24 hours post AOM injection (P= 
0.36). Overall Bik gene expression pattern in colon and liver show significant differences 
(P=0.04) without a meaningful difference at each specific time point (Fig.17-E and Fig. 
19-E). Also, Bak gene expression pattern is significantly different over 24 hours post 
injection between the two tissues (P=0.007) (Fig.17-F and 19-F). Furthermore, refer to 
figures 17 and 19 panels D, which show the Bad gene expression patterns in colon and 
liver, respectively, this pro-apoptotic gene did not show significantly different expression 
patterns in these particular tissues, since based on the two-way ANOVA test the P value 
is 0.18 with 95% confidence interval. A statistical comparison between results of Fig.17-
B and 19-B indicated that anti-apoptotic Bcl-XL gene expression pattern in colon tissue is 
not significantly different from liver. The same result was achieved for the anti-apoptotic 
Bcl-2 with no significant difference in its overall gene expression patterns in liver and 
colon (Fig.17-A and 19-A), while P53 gene expression pattern is significantly different in 
liver and colon tissue within 24 hours after carcinogen injection (P=0.006) (Fig.18 and 
Fig.20). 
In fact, it seems that the ability to remove or repair the initial damage is probably more 
important than the damage itself in determining the increase and/or decrease in either the 
tumor development or apoptosis index. Hong et. al. suggested that a higher apoptotic 
index is observed in liver within the first 12 hours post AOM injection in mice model 
(63). In current study, P53 and its pro-apoptotic down-stream target genes Bax, Bik, Bak, 
and Bad expression levels are significantly different between colon and liver tissues 
within 24 hours after AOM injection in both lean and obese Zucker rats. Interestingly, 
anti-apoptotic Bcl-2 and Bcl-XL genes did not show a significant difference in these two 
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tissues. As expected, in colon and liver tissues the apoptotic index could be different, 
since pro-apoptotic gene expressions are different, and actually it seems that the tumor 
suppressor P53 and pro-apoptotic gene expression levels in liver tissue are higher than 
what it is colon within twenty four hours post AOM injection.  Therefore, current results 
in Zucker rats confirm the previous results in other animal models and suggest that after 
apoptotic signal, liver tissue could be more prone to cell death. However, other factors 
should be considered to explain the grater sensitivity of colon to AOM induced 
tumorogenesis compared to liver. One important factor is the higher rate of cell turnover 
in colon, which would increase the chance that DNA synthesis would occur while the 
carcinogen-induced damage has not been repaired yet. Therefore, persistence and 
accumulation of damaged DNA through replication must be the initiator of 
tumorogenesis in colon tissue compared to liver. Therefore, more investigation on genes 
and proteins that are involved in cell proliferation and DNA repair system as well as 
applying other techniques such as morphological studies and TUNEL assay to show the 
real apoptosis index in these two tissues is required. 
 
This was the first study comparing the expression level of BCL-2 family of genes in 
obese versus lean liver and colon tissue. As described earlier, during initial stages of 
carcinogen-induced DNA damage, apoptotic index increases in order to remove the cells 
with damaged DNA along with other repair mechanisms. However, in some tissues with 
grater cell turnover rate such as colonic mucosa, some cells continue DNA replication 
and proliferation while their genomic pool has not been repaired, although the rate of cell 
death has been increase because of carcinogen injection. Accumulation of damaged 
DNA, accompanied by mutations in late stages of carcinogen administration leads to 
tumorogenesis. On the other hand, in some organs such as liver, where the cell 
proliferation rate is not high, keeping the tight balance between cell proliferation and 
death is critical in their normal function. Therefore, more apoptosis compared to cell 
proliferation makes the tissue more susceptible to disease progression. In this study, it 
was shown that an obese genotype affects pro- and anti-apoptotic gene expression levels 
and patterns whether or not DNA damage has been induced in these tissues. The results 
show a clear alteration in apoptotic gene expression levels in obese animals compared to 
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their lean counterparts leading to the proposal that apoptosis may be involved in the 
obesity related colon and liver pathogenesis. Moreover, differential apoptotic gene 
expression analysis is one of the techniques of measuring cell death rate. However, in 
some cases, due to post translational and transcriptional modifications, apoptotic proteins 
may present a different expression level from genes. Also, pro- and anti-apoptotic protein 
conformations may affect the apoptosis rate as well. Therefore, it is better to apply other 
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